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Atherosclerosis	  is	  an	  inflammatory	  disorder	  of	  the	  vasculature	  leading	  to	  the	  
development	  of	  plaques	  within	  vessel	  walls.	  A	  critical	  component	  of	  atherosclerosis	  
involves	  migration	  and	  proliferation	  of	  vascular	  smooth	  muscle	  cells	  (VSMCs)	  into	  the	  
developing	  plaque,	  however,	  its	  mechanism	  is	  not	  yet	  understood.	  	  
Previous	  studies	  have	  reported	  that	  IL-­‐‑2	  is	  deposited	  within	  the	  vasculature	  
and	  IL-­‐‑2	  accumulates	  within	  atherosclerotic	  plaques	  due	  to	  secretion	  by	  infiltrating	  
Th-­‐‑1	   cells.	   A	   limited	   number	   of	   studies	   suggest	   that	   VSMCs	   express	   a	   partial	   IL-­‐‑2	  
receptor,	   comprising	   the	   β	   and	   γ	   subunit.	   This	   suggests	   that	   IL-­‐‑2	   may	   elicit	   a	  
physiological	   response	   in	   VSMCs.	   Considering	   IL-­‐‑2’s	   proliferative	   function	   among	  
cells	   of	   the	   immune	   system,	   we	   hypothesized	   that	   VSMCs	   respond	   to	   IL-­‐‑2	   by	  
proliferation	  and	  migration	  in	  vitro.	  Since	  the	  IL-­‐‑2	  receptor	  has	  the	  highest	  affinity	  as	  
a	  heterotrimeric	  protein	  comprised	  of	  α,	  β,	  and	  γ	  subunits,	  it	  is	  likely	  that	  VSMCs	  also	  
express	  the	  IL-­‐‑2	  receptor	  α	  subunit.	  
We	  observed	  a	  pronounced	  increase	  of	  DNA	  synthesis	  in	  IL-­‐‑2	  treated	  VSMCs	  
by	  using	  the	  CLICK-­‐‑IT	  assay.	  Using	  the	  Boyden	  Chamber	  assay,	  we	  showed	  that	  IL-­‐‑2	  
	   iv	  
caused	  significant	  VSMC	  migration.	  IL-­‐‑2R	  α	  mRNA	  was	  detected	  in	  VSMCs	  by	  RT-­‐‑PCR	  
using	  intron-­‐‑spanning	  primers	  and	  confirmed	  by	  sequencing.	  IL-­‐‑2	  receptor	  α	  protein	  
of	   the	   expected	  molecular	  weight	  was	   observed	   in	   VSMC	   lysates	   by	  western	   blot	  
analysis	   using	   a	   protein	   specific	   antibody.	   Additional	   studies	   using	  
immunofluorescence	  and	  cell-­‐‑fractionation	  revealed	  that	  IL2R	  α	  subunit	  localizes	  to	  
the	  nuclear	  envelope	  of	  VSMCs.	  Finally,	  we	  have	  found	  IL-­‐‑2	  activates	  the	  MAPK	  and	  
PI3K/AKT	  signaling	  pathways	  within	  VSMCs.	  	  
Expression	   of	   the	   tripartite	   IL-­‐‑2	   receptor	   (α,	   β,	   γ)	  within	  VSMCs	   is	   a	   novel	  
observation.	   Working	   through	   this	   receptor	   IL-­‐‑2	   may	   induce	   proliferation	   and	  
migration	   of	   VSMC’s	   into	   sites	   of	   developing	   plaques	   thereby	   contributing	   to	   the	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ATHEROSCLEROSIS	  AND	  IL-­‐‑2	  
The	  Case	  for	  Studying	  IL-­‐‑2	  and	  its	  Possible	  Role	  in	  Atherosclerosis	  
	  
	  
Cardiovascular	  Disease:	  	  
	  
Cardiovascular	  disease	  is	  currently	  the	  primary	  cause	  of	  death	  in	  the	  United	  
States.	   Each	   year,	   an	   average	   of	   610,000	   Americans	   die	   from	   some	   form	   of	  
cardiovascular	  disease	  (Kochanek,	  Murphy,	  Xu,	  &	  Arias,	  2014).	  The	  main	  risk	  factors	  
contributing	  to	  cardiovascular	  disease	  are	  high	  blood	  pressure,	  high	  cholesterol,	  and	  
smoking.	   Over	   50%	   of	   adults	   in	   the	   United	   States	   have	   at	   least	   one	   of	   these	   risk	  
factors.	  Although	  there	  is	  evidence	  that	  individuals	  may	  have	  a	  genetic	  predisposition,	  
the	  primary	  factors	  associated	  with	  the	  pathogenesis	  of	  cardiovascular	  disease	  are	  
poor	  diet	  and	  lack	  of	  adequate	  physical	  activity	  (Dai,	  Wiernek,	  Evans,	  Runge,	  2016;	  
Schuett,	  Lehrke,	  Marx,	  	  Burgmaier,	  2015).	  
Developing	  nations	  are	  experiencing	  a	  rise	  in	  the	  incidence	  of	  cardiovascular	  
disease;	   For	   example,	   India’s	   total	   population	   rose	   by	   20%	  within	   the	   last	   fifteen	  
years,	  while	  its	  reported	  incidence	  of	  cardiovascular	  disease	  has	  more	  than	  doubled	  
in	  that	  same	  time	  period	  (Chauhan	  and	  Aeri	  2015).	  Such	  a	  sharp	  increase	  is	  common	  
among	   other	   developing	   nations	   and	   coincides	   with	   a	   world-­‐‑wide	   shift	   toward	   a	  
western	  diet	  high	  in	  fats,	  animal	  products,	  and	  refined	  carbohydrates	  (Hu	  2008;	  Singh	  
et	  al.	  2014).	  The	  quintessence	  of	  a	  high-­‐‑fat	  western	  diet	  is	  the	  consumption	  of	  fast	  
food.	  Its	  demand	  in	  China	  has	  doubled	  since	  1999,	  significantly	  increasing	  the	  risk	  for	  
	   2	  
cardiovascular	  disease	  among	  its	  population	  (Angelica	  and	  Fong	  2008).	  The	  World	  
Health	  Organization	  has	  declared	  that	  30%	  of	  all	  deaths	  worldwide	  are	  a	  result	  of	  
cardiovascular	  disease.	  Thus,	  cardiovascular	  disease	  is	  not	  just	  a	  national	  concern	  but	  
a	  global	  epidemic.	  
The	  major	  cause	  for	  mortality	  from	  cardiovascular	  disease	  is	  atherosclerosis,	  
which	  is	  the	  hardening	  of	  arteries	  from	  calcified,	  cholesterol	  laden,	  necrotic	  cores	  of	  
the	   intimal	   layer	   (Bentzon	   et	   al.	   2014).	   Atherosclerosis	   results	   from	   a	   self-­‐‑
perpetuating	  cycle	  of	  chronic	  inflammation	  of	  the	  medium	  and	  large	  arteries,	  which	  
causes	  aggregation	  of	  cholesterol	  within	  macrophages	  and	  vascular	  smooth	  muscle	  
cells	   (VSMCs).	   This	   inevitably	   leads	   to	   more	   inflammation	   by	   transforming	  
macrophages	  and	  vascular	  smooth	  muscle	  cells	  into	  pro-­‐‑inflammatory	  cells	  known	  as	  	  
“foam	  cells”	   (Kleemann,	  Zadelaar,	   and	  Kooistra	  2008).	   	  Over	   the	   course	  of	   several	  
years,	   this	   process	   leads	   to	   plaque	   formation,	   aggregation	   of	   necrotic	   debris,	   and	  
subsequent	   calcification	   of	   tissue	   enclosed	   by	   fibrosis.	   	   Eventually	   the	   plaque	  
ruptures	   and	   occludes	   important	   arterial	   vessels	   leading	   to	   fatal	   pathological	  
conditions	  (Davies	  2000).	  	  
There	  are	  four	  distinct	  stages	  that	  are	  commonly	  observed	  in	  atherosclerosis	  
(figure	   1):	   (1)	   Initiation	   of	   endothelial	   activation	   (2)	   promotion	   of	   foam	   cell	  
formation	  (3)	  progression	  of	  plaques	  and	  (4)	  precipitation	  of	  acute	  clinical	  events.	  	  
	   An	   individual	   maintaining	   an	   elevated	   plasma	   cholesterol	   concentration	  
through	   diet	   or	   genetic	   abnormality	   accumulates	   low-­‐‑density	   lipoprotein	   (LDL)	  
throughout	   the	   intimal	   layer	   of	   the	   vasculature;	   this	   places	   them	   at	   high	   risk	   for	  
developing	   atherosclerosis	   (Magill	   et	   al.	   2010).	   During	   the	   initiation	   phase	   of	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atherosclerosis,	   vascular	   endothelial	   cells	   become	   activated	   as	   a	   result	   of	   slow	   or	  
turbulent	   blood	   flow.	   Activated	   endothelial	   cells	   release	   chemokines	   that	   attract	  
monocytes	   and	   neutrophils.	   Significant	   thickening	   of	   the	   vasculature,	   known	   as	  
intimal	  hyperplasia,	  occurs	  via	  VSMC	  migration	  from	  the	  tunica	  media	  into	  the	  intima	  
(Chistiakov,	   Orekhov,	   and	   Bobryshev	   2015).	   During	   the	   promotion	   stage,	  
macrophages	   and	   VSMCs	   within	   the	   tunica	   intima	   absorb	   deposited	   LDLs	   and	  
transform	   into	   pro-­‐‑inflammatory	   cells	   known	   as	   foam	   cells.	   These	   are	   grossly	  
observed	  as	  yellow	  lines	  on	  the	  vasculature	  termed	  	  “fatty	  streaks”	  (Stary	  et	  al.	  1994).	  
Progression	   of	   atherosclerosis	   is	   marked	   by	   plaque	   formation	   through	  
swelling	  of	  the	  intimal	  layer	  via	  proliferation	  of	  vascular	  smooth	  muscle,	  fibroblasts,	  
and	   immune	   cells.	   Increased	   cell	   turnover	   rapidly	   depletes	   nutrients	   and	   exposes	  
cells	   to	   prolonged	   oxidative	   conditions;	   this	   leads	   to	   necrosis	   and	   subsequent	  
calcification	  of	   the	   tissue	   (Stary	  2001).	   Smooth	  muscle	   cell	   deposition	  of	   collagen,	  
elastin,	   and	   proteoglycans	   promote	   fibrosis,	   which	   drives	   the	   stabilization	   of	   a	  
developing	  plaque	  (Barnes	  and	  Farndale	  1999).	  	  Fibrosis	  and	  increased	  extracellular	  
matrix	   causes	   increased	   elastance.	   This	   stiffening	   of	   the	   vessels	   results	   in	   higher	  
turbulence	  of	  blood	  flow	  which	  initiates	  further	  plaque	  formation.	  	  
Finally,	   the	   precipitation	   of	   acute	   clinical	   events	   arises	   when	   the	   plaque	  
becomes	  unstable	  and	  ruptures.	  Debris	  released	  from	  the	  rupture	  promotes	  systemic	  
thrombosis,	   which	   occludes	   the	   vasculature.	   The	   resulting	   ischemia	   leads	   to	  
dysfunction	   of	   vital	   organs	   and	   life-­‐‑threatening	   conditions	   such	   as	   myocardial	  
infarction,	  seizures,	  ventricular	  fibrillation,	  neuropathy,	  and	  organ	  failure.	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VSMCs	  in	  Atherosclerosis	  
One	  of	  the	  least	  understood	  aspects	  of	  plaque	  formation	  is	  the	  role	  of	  vascular	  
smooth	  muscle	  cells	  (VSMCs).	  VSMCs	  are	  contractile	  cells	  embedded	  within	  the	  tunica	  
media	  of	  arteries	  and	  veins.	  This	  layer	  is	  located	  just	  beneath	  the	  endothelial	  layer	  
called	  the	  tunica	  intima	  (Johansson	  1975).	  VSMCs	  are	  a	  heterogenous	  population	  that	  
cycles	  between	  two	  morphologically	  distinct	  phenotypes:	  contractile	  and	  synthetic.	  	  
Contractile	   type	   VSMCs	   are	   differentiated,	   non-­‐‑proliferative	   cells	   that	  
transform	   into	   a	   more	   proliferative	   phenotype	   under	   inflammatory	   conditions.	   A	  
subpopulation	   of	   VSMCs	  within	   the	   tunica	  media	   labeled	  multivascular	   stem	   cells	  
(MVSMCs)	   are	   believed	   to	   be	   the	   dominant	   cells	   that	   proliferate	   and	   differentiate	  
under	   inflammatory	   conditions	   (Orlandi	   2015).	   Although	   VSMC	   proliferation	   and	  
differentiation	  during	  atherosclerosis	   remain	   largely	   ill-­‐‑defined,	  we	   can	  be	   certain	  
they	  play	  an	  important	  role	  in	  the	  pathogenesis	  of	  atherosclerosis.	  
	  
Potential	  link	  between	  IL-­‐‑2	  and	  Atherosclerosis	  
Inflammation	  is	  maintained	  by	  the	  functions	  of	  a	  myriad	  of	  cytokines	  during	  
the	   progression	   of	   atherosclerosis.	   Numerous	   studies	   utilizing	   animal	   models	   of	  
atherosclerosis,	   such	   as	   apoE-­‐‑/-­‐‑	   and	   LDLr	   -­‐‑/-­‐‑	   mice,	   have	   demonstrated	   that	   the	  
following	   cytokines	  promote	   the	  progression	  of	   atherosclerosis:	   IL-­‐‑1,	   IL-­‐‑12,	   IL-­‐‑18,	  
TNF-­‐‑α,	  MIF,	  IFN-­‐‑γ,	  and	  M-­‐‑CSF	  (Tabas,	  García-­‐‑Cardeña,	  and	  Owens	  2015).	  Conversely,	  
IL-­‐‑10	  has	  been	  reported	  to	  strongly	  inhibit	  such	  progression	  (Caligiuri	  et	  al.	  2003)	  
while	  other	  cytokines,	  for	  example,	  IL-­‐‑4,	  IL-­‐‑6,	  and	  GM-­‐‑CSF,	  have	  yielded	  conflicting	  
results	   regarding	   their	   role	   in	   the	  progression	  of	   atherosclerosis	   (Kleemann	  et	   al.,	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2008).	  Thus,	  on	  the	  matter	  of	  understanding	  cytokines	  and	  their	  specific	  roles	  in	  the	  
progression	   of	   atherosclerosis,	   there	   is	   much	   work	   to	   be	   done.	   A	   better	  
understanding	   of	   the	   complete	   scope	   of	   cytokine	   contribution	   toward	   the	  
advancement	  of	  atherosclerosis	  would	  offer	  new	  therapeutic	  targets	  for	  inhibiting	  the	  
progression	  of	  the	  disease.	  	  
	   Interleukin-­‐‑2	   (IL-­‐‑2),	   a	   T-­‐‑cell	   growth	   factor,	   has	   been	   associated	   with	   the	  
progression	  of	  atherosclerosis	  by	  a	  few	  laboratories.	  Intraperitoneal	  injections	  of	  IL-­‐‑
2	   in	   apoE-­‐‑/-­‐‑	  mice	  were	   reported	   to	   accelerate	   the	   progression	   of	   atherosclerosis	  
while	   administration	   of	   anti-­‐‑IL-­‐‑2	   antibodies	   exerted	   a	   protective	   effect	   (Upadhya,	  
Mooteri,	  Peckham,	  &	  Pai,	  2004).	  In	  two	  cohort	  studies	  monitoring	  human	  volunteers,	  
serum	   IL-­‐‑2	   concentrations	   correlated	   with	   the	   severity	   of	   atherosclerosis	   found	  
within	   the	   carotid	   and	   coronary	   arteries	   (Ding	   et	   al.	   2013;	   Elkind	   et	   al.	   2005).	  
Although	  these	  studies	  implicate	  IL-­‐‑2	  as	  a	  potentially	  important	  factor	  involved	  in	  the	  
progression	  of	  atherosclerosis,	  an	  understanding	  of	  the	  underlying	  mechanism	  is	  still	  
lacking.	  
IL-­‐‑2	   is	   a	   cytokine	   discovered	   due	   to	   its	   potency	   in	   functioning	   as	   a	   T-­‐‑cell	  
growth	   factor	   (Ju	   et	   al.	   1987;	  Morgan,	  Ruscetti,	   and	  Gallo	  1976).	   IL-­‐‑2	   is	   known	   to	  
induce	   proliferation	   and	  migration	   in	  many	   immune	   cells	   including	   natural	   killer	  
(NK)	  cells,	  B	  cell	  and	  T-­‐‑regulatory	  cells	  (Liao,	  Lin,	  and	  Leonard	  2013).	  IL-­‐‑2	  elicits	  its	  
function	  by	  binding	  to	  its	  receptor	  which	  is	  comprised	  of	  three	  subunits:	  IL-­‐‑2Rα,	  	  IL-­‐‑
2Rβ,	  and	  IL-­‐‑2Rγ	  (Pillet	  et	  al.	  2010).	  The	  heterodimerization	  of	  IL-­‐‑2Rβ	  and	  IL-­‐‑2Rγ	  is	  
responsible	  for	  signaling	  transduction.	  The	  resulting	  signal	  is	  carried	  via	  three	  main	  
phosphorylation	  mediated	  pathways:	  Janus	  Kinase	  (JAK),	  phosphoinositide	  3-­‐‑kinase	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(PI3K)-­‐‑AKT,	   and	   mitogen-­‐‑activated	   protein	   kinase	   (MAPK).	   These	   pathways	  
generally	  promote	  survival,	  activation	  and	  proliferation	  of	  the	  target	  cell	  (Imada	  and	  
Leonard	  2000;	  W.	  Kuziel	  and	  Greene	  1990).	  
In	  addition	  to	  binding	  to	  IL-­‐‑2,	  IL-­‐‑2Rβ	  serves	  as	  the	  β	  component	  for	  the	  IL-­‐‑15	  
receptor.	  Similarly,	  IL-­‐‑2Rγ	  functions	  as	  an	  integral	  portion	  of	  IL-­‐‑4,	  IL-­‐‑7,	  IL-­‐‑9,	  IL-­‐‑15,	  
and	  IL-­‐‑21	  receptors	  (Liao	  et	  al.	  2013).	  Both	  IL-­‐‑2Rβ	  and	  IL-­‐‑2Rγ	  have	  been	  documented	  
by	  histological	  studies	  in	  VSMCs.	  (Hocke	  et	  al.	  2007;	  Hofbauer	  et	  al.	  2006).	  Studies	  
from	  our	  laboratory	  have	  subsequently	  solidified	  these	  presence	  of	  the	  IL-­‐‑2Rβ	  
In	  our	  recent	  publication	  we	  reported	  the	  deposition	  of	  IL-­‐‑2	  within	  the	  smooth	  
muscle	  layer	  of	  the	  aorta	  (Miller	  et	  al.	  2012).	  Due	  to	  IL-­‐‑2’s	  co-­‐‑localization	  with	  	  VSMCs	  
in	  the	  tunica	  media	  and	  the	  expression	  of	  IL-­‐‑2	  receptor	  subunits	  on	  VSMCs,	  we	  asked	  
the	  following	  questions:	  
1.   Does	  IL-­‐‑2	  influence	  VSMC	  physiology?	  If	  so,	  how?	  
2.   Is	  the	  IL-­‐‑2	  receptor	  α	  expressed	  on	  VSMCs?	  
3.   What	  signaling	  mechanisms,	  if	  any,	  are	  activated	  in	  VSMCs	  by	  IL-­‐‑2?	  
4.   Are	  IL-­‐‑2	  mediated	  functions	  pertinent	  to	  the	  pathogenesis	  of	  Atherosclerosis?	  
Since	  IL-­‐‑2Rβ	  and	  IL-­‐‑2Rγ	  components	  have	  been	  reported	  in	  VSMCs,	  it	  is	  likely	  that	  
IL-­‐‑2Rα	  is	  	  also	  present	  in	  VSMCs.	  In	  lymphocytes	  IL-­‐‑2	  mediates	  heterodimerization	  
of	  the	  IL-­‐‑2Rβ	  and	  IL-­‐‑2Rγ	  whereby	  initiating	  an	  intracellular	  signal	  that	  results	   in	  a	  
physiological	  response.	  VSMCs	  express	  both	  the	  IL-­‐‑2Rβ	  and	  IL-­‐‑2Rγ	  subunits;	  this	  led	  
us	   to	  believe	   that	  VSMCs	  must	  be	  capable	  of	  binding	   IL-­‐‑2.	  Considering	   IL-­‐‑2’s	  well-­‐‑
characterized	   proliferative	   and	   migratory	   function	   among	   immune	   cells,	   and	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considering	  VSMC’s	  expression	  of	  the	  IL-­‐‑2	  receptor	  β	  and	  IL-­‐‑2	  receptor	  γ	  subunits,	  we	  
hypothesized	  the	  following:	  	  
	  
“IL-­‐‑2	  causes	  proliferation	  and	  migration	  of	  vascular	  smooth	  muscle	  cells	  
of	  the	  aorta.	  IL-­‐‑2	  elicits	  this	  function	  through	  the	  IL-­‐‑2	  receptor	  using	  established	  
signaling	  pathways.”	  
	  
We	  organized	  our	  approach	  for	  determining	  the	  role	  of	  IL-­‐‑2	  in	  VSMC	  physiology	  into	  
three	  specific	  aims:	  	  
	  
Specific	   Aim	   1:	   Determine	   the	   Functions	   of	   IL-­‐‑2	   in	   Vascular	   Smooth	  Muscle	  
(Chapters	  3	  and	  4)	  
The	   overall	  objective	   of	   this	   specific	   aim	  was	   to	   elucidate	   the	   effect	   of	   IL-­‐‑2	   on	  
VSMCs.	   The	   rationale	   of	   this	   specific	   aim	   was	   that	   the	   most	   dominant	   and	   well	  
characterized	   functions	   of	   IL-­‐‑2	   are	   to	   promote	   proliferation	   and	   migration	   of	  
lymphoid	   cells	   (Liao,	   J.	   X.	   Lin,	   and	   Leonard	   2011).	   VSMCs	   contain	   the	   β	   and	   γ	  
components	  of	  the	  IL-­‐‑2	  receptor	  (Hocke	  et	  al.	  2007;	  Hofbauer	  et	  al.	  2006),	  	  making	  it	  
likely	   that	   IL-­‐‑2	   binds	   VSMCs	   using	   IL-­‐‑2	   receptors	   and	   promotes	   proliferation	   and	  
migration	  of	  VSMCs.	  	  	  
To	  determine	  whether	  IL-­‐‑2	  elicits	  a	  proliferative	  response	  within	  VSMCs,	  primary	  
VSMCs	   prepared	   from	   human	   aortas	   were	   treated	   with	   IL-­‐‑2	   at	   a	   physiologically	  
relevant	   concentration.	   Cell	   proliferation	   in	   primary	   VSMCs	   was	   quantified	   using	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multiple	  assays	  that	  measure	  relative	  cell	  number	  and	  DNA	  synthesis.	  We	  found	  that	  
IL-­‐‑2	  promotes	  VSMC	  proliferation.	  
To	  assess	  the	  ability	  of	  IL-­‐‑2	  to	  induce	  migration	  of	  VSMCs,	  primary	  smooth	  muscle	  
cells	   prepared	   from	   human	   aortas	   were	   subject	   to	   Boyden	   chamber	   assay	   using	  
various	   physiologically	   relevant	   concentrations	   of	   IL-­‐‑2.	   We	   concluded	   that	   IL-­‐‑2	  
causes	  migration	  of	  VSMCs.	  
To	  emulate	   in-­‐‑vivo	   conditions	  of	   IL-­‐‑2	   induced	  VSMC	  proliferation,	   explants	  were	  
prepared	   from	   human	   aortas	   and	   exposed	   to	   various	   concentrations	   of	   IL-­‐‑2.	  
Subsequently,	  migrating	   and	  proliferating	   smooth	  muscle	   cells	  were	  quantified	  by	  
imaging	  and	  the	  Alamar	  Blue	  assay.	  The	  Alamar	  Blue	  assay	  uses	  metabolic	  activity	  to	  
measure	  relative	  cell	  number.	  We	  found	  that	  IL-­‐‑2	  addition	  caused	  a	  significant	  rise	  in	  
VSMC	  outgrowth	  from	  explants.	  Cells	  emerging	  from	  the	  explant	  were	  verified	  to	  be	  
VSMCs	  by	  confirming	  the	  expression	  of	  α	  SMC	  actin,	  a	  known	  VSMC	  marker,	  using	  
western	  blot	  detection.	  	  
Specific	   Aim	   2:	   Verify	   IL-­‐‑2	   Receptor	   Presence	   in	   Vascular	   Smooth	   Muscle	  
(Chapter	  5)	  
The	   objective	   of	   this	   specific	   aim	   was	   to	   establish	   the	   presence	   of	   the	  
components	  of	  IL-­‐‑2	  receptor	  on	  VSMCs.	  The	  rationale	  for	  this	  specific	  aim	  was,	  since	  
the	  complete	  IL-­‐‑4	  and	  IL-­‐‑15	  receptors	  have	  been	  discovered	  on	  VSMCs,	  the	  idea	  of	  
cytokine	   receptors	   being	   found	   on	   these	   non-­‐‑lymphoid	   cells	   is	   no	   longer	   peculiar	  
(Hocke	   et	   al.	   2007;	   Hofbauer	   et	   al.	   2006).	   Interestingly,	   the	   IL-­‐‑15	   receptor	   β	  
component	  and	  IL-­‐‑4	  receptor	  γ	  components	  dually	  function	  as	  the	  IL-­‐‑2	  receptor	  β	  and	  
γ	  components	  respectively	  (W.	  A.	  Kuziel	  and	  Greene	  1990).	  Since	  the	  heterotrimeric	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IL-­‐‑2	  receptor	  is	  functional	  in	  lymphocytes	  (Greene	  et	  al.	  1989),	  it	  is	  likely	  that	  VSMCs	  
also	  express	  the	  α	  component.	  	  
To	  ascertain	  presence	  of	  the	  IL-­‐‑2	  receptor	  proteins,	  the	  VSMC	  lysates	  from	  our	  
cultures	  were	  analyzed	  using	  SDS-­‐‑page.	  IL-­‐‑2	  receptor	  components	  were	  probed	  using	  
western	  blot	  analysis	  and	  the	  sizes	  of	  the	  resulting	  bands	  were	  compared	  with	  those	  
from	  lymphocytic	  lysates.	  We	  found	  the	  presence	  all	  three	  IL-­‐‑2	  receptor	  component	  
proteins.	  	  
To	   establish	   the	   presence	   of	   transcriptional	   message	   of	   the	   IL-­‐‑2	   receptor	  
components,	  total	  mRNA	  was	  isolated	  from	  VSMCs,	  then	  the	  corresponding	  cDNA	  was	  
amplified	  and	  sequenced.	  The	  sequenced	  data	  was	  compared	  with	  known	  sequences	  
found	  in	  Genbank;	  this	  confirmed	  the	  sequences	  to	  be	  for	  IL-­‐‑2	  receptor	  components.	  	  
To	   determine	   cellular	   localization	   of	   the	   IL-­‐‑2	   receptor,	   we	   utilized	  
immunostaining	  of	  VSMCs	  by	  visualizing	  each	  IL-­‐‑2	  receptor	  subunit.	  This	  was	  done	  
using	  confocal	  microscopy	  and	  cell	  fractionation	  in	  combination	  with	  western	  blot.	  
We	  found	  the	  presence	  of	  IL-­‐‑2R	  β	  and	  IL-­‐‑2R	  γ	  in	  the	  cytoplasmic	  membrane	  and	  the	  
nuclear	  membrane.	  IL-­‐‑2R	  α	  was	  primarily	  found	  in	  the	  nuclear	  membrane	  and	  the	  
cytoplasm.	  Immunofluorescence	  and	  cell	  fractionation	  data	  both	  consistently	  showed	  
that	  the	  IL-­‐‑2R	  α	  localizes	  tothe	  nuclear	  and	  cytoplasmic	  fractions,	  while	  the	  IL-­‐‑2R	  β	  
and	  γ	  localize	  to	  the	  nuclear	  and	  cell	  membrane	  fractions.	  	  
In	  summary,	  we	  identified	  the	  presence	  of	  the	  complete	  heterotrimeric	  IL-­‐‑2	  
receptor	  mRNA	  and	  proteins	  within	  primary	  human	  VSMC	  originating	  from	  multiple	  
donors.	  The	  predisposition	  of	  these	  receptors	  to	  the	  nucleus	  is	  a	  novel	  finding	  and	  
very	  perplexing.	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Specific	  aim	  3:	  IL-­‐‑2	  mediated	  signaling	  in	  VSMCs	  (Chapter	  6)	  
The	   objective	   of	   this	   specific	   aim	   was	   to	   determine	   if	   signaling	   pathways	  	  
activated	   in	   lymphocytes	   in	   response	   to	   IL-­‐‑2	   are	   also	   activated	   in	   VSMCs.	   The	  
rationale	  for	  this	  specific	  aim	  was	  that	  the	  heterodimerization	  of	  IL-­‐‑2Rβ	  and	  IL-­‐‑2Rγ	  
is	   responsible	   for	  signaling	   transduction	  and	  both	  of	   these	  components	  have	  been	  
confirmed	  in	  VSMCs.	  The	  resulting	  signal	  is	  carried	  via	  three	  main	  phosphorylation	  
mediated	  pathways	  in	  lymphocytes:	   Janus	  Kinase	  (JAK),	  phosphoinositide	  3-­‐‑kinase	  
(PI3K)-­‐‑AKT,	  and	  mitogen-­‐‑activated	  protein	  kinase	  (MAPK).	  Since	  IL-­‐‑2Rβ	  and	  IL-­‐‑2Rγ	  
are	  also	  expressed	  in	  VSMCs	  (Hocke	  et	  al.	  2007;	  Hofbauer	  et	  al.	  2006),	  it	  is	  likely	  that	  
the	  same	  signaling	  pathways	  are	  activated	  in	  VSMCs.	  
1.   To	  implicate	  the	  MAPK	  pathway	  in	  IL-­‐‑2	  mediated	  signaling	  in	  VSMCs,	  ERK,	  p38	  
and	  JNK	  were	  monitored	  for	  phosphorylation.	  
2.   To	  implicate	  the	  PI3K/AKT/P70S6K	  pathway	  in	  IL-­‐‑2	  mediated	  signaling	  in	  VSMCs	  	  	  
AKT	  and	  p70S6K	  were	  monitored	  for	  phosphorylation.	  	  
We	   found	   that	   both	   the	   MAPK	   pathway	   and	   the	   PI3/AKT/p70S6K	   pathways	   are	  
activated	  in	  VSMCs	  in	  response	  to	  IL-­‐‑2.	  	  
We	   have	   generated	   strong	   evidence	   showing	   that	   IL-­‐‑2	   influences	   VSMC	  
physiology.	  IL-­‐‑2	  promotes	  VSMC	  proliferation	  and	  migration	  in	  vitro	  and	  in	  situ.	  We	  
discovered	   the	   presence	   of	   the	   IL-­‐‑2	   receptor	   α,	   which	   is	   a	   novel	   finding,	   and	  
confirmed	   the	   presence	   of	   IL-­‐‑2	   receptor	   β	   and	   γ.	   We	   later	   showed	   major	   IL-­‐‑2	  
mediated	  signaling	  pathways	  are	  activated	  in	  VSMCs	  in	  response	  to	  IL-­‐‑2	  treatment.	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Our	   observation	   of	   VSMC’s	   physiological	   response	   to	   IL-­‐‑2	   and	   the	   activation	   of	  
signaling	  pathways	  associated	  with	   IL-­‐‑2	  mediated	  activation,	   together	  support	   the	  
narrative	  that	  IL-­‐‑2	  causes	  cell-­‐‑survival,	  cell	  proliferation	  and	  cell	  migration	  in	  VSMCs.	  
VSMC	   proliferation	   and	  migration	   encompasses	   a	   critical	   stage	   of	   atherosclerosis,	  
























VASCULAR	  SMOOTH	  MUSCLE	  PHYSIOLOGY	  AND	  PRIMARY	  CULTURE	  
TECHNIQUES	  
Vascular	  Smooth	  Muscle	  
There	  are	   three	  main	   types	  of	  muscle	  groups:	  smooth,	  cardiac	  and	  skeletal.	  
Skeletal	  muscle	  is	  under	  the	  control	  of	  somatic	  motor	  neurons.	  Cardiac	  and	  smooth	  
muscle	  are	  under	  the	  control	  of	  autonomic	  nervous	  system.	  All	  muscle	  cells	  express	  
cross-­‐‑bridge	   forming	   contractile	   proteins	   called	   actin	   and	   myosin.	   The	   combined	  
length	   of	   actin	   and	   myosin	   is	   reduced	   or	   expanded	   in	   order	   to	   produce	   cellular	  
contraction	   and	   relaxation	   respectively	   (Webb	  2003).	   Cardiac	   and	   skeletal	  muscle	  
both	  show	  regularly	  spaced	  bands	  of	  these	  contractile	  proteins.	  Smooth	  muscle	  lacks	  
such	  banding	  patterns.	  Smooth	  muscle	  exhibits	  slow	  and	  sustained	  contraction,	  while	  
cardiac	  muscle	  contraction	  tends	  to	  be	  rapid	  and	  relatively	  short	  in	  duration	  (Harris	  
et	  al.	  1994).	  
Smooth	  muscle,	  in	  addition	  to	  being	  an	  integral	  component	  of	  the	  vasculature,	  
serves	  numerous	  vital	  roles	  across	  multiple	  organ	  systems.	  In	  the	  gastro-­‐‑intestinal	  
tract,	   it	   is	   responsible	   for	   the	   rhythmic	   contractions	   known	   as	   peristalsis	   that	  
mobilizes	   ingested	   food	  (Sanders	  et	  al.	  2012).	   In	   the	  bladder,	   the	  detrusor	  smooth	  
muscle’s	  capacity	  to	  contract	  and	  relax	  dictate	  the	  bladder’s	  function	  during	  bladder	  
filling	  and	  micturition	  (Van	  Mastrigt	  2002).	   	  Smooth	  muscle	  also	  serves	   important	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functions	   in	   the	   uterus,	   reproductive	   tracts,	   and	   eye	   (Samuel,	   Lutjen-­‐‑Drecoll,	   and	  
Tamm	  1996)	  	  	  
Vascular	  smooth	  muscle	  cells	  (VSMCs)	  comprise	  a	  specialized	  type	  of	  smooth	  
muscle	  embedded	  within	  the	  tunica	  media	  of	  arteries	  and	  veins.	  The	  tunica	  media	  
layer	  lies	  just	  beneath	  the	  thin	  endothelial	  layer	  called	  the	  tunica	  intima	  (Johansson	  
1975).	  VSMCs	  perform	  the	  executive	  function	  of	  regulating	  total	  body	  blood	  pressure	  
by	  adjusting	  the	  diameter	  of	  vasculature	  in	  response	  to	  autonomic	  neuronal	  signaling	  
(Burnstock	   1975).	   Smooth	   muscle	   is	   integral	   to	   vascular	   remodeling	   during	  
pregnancy,	  exercise,	  and	  injury	  through	  its	  proliferation	  and	  secretion	  of	  extracellular	  
matrix	  (Zempo	  et	  al.	  1996).	  	  
Contraction	  of	  VSMCs	  can	  be	  initiated	  by	  mechanical,	  electrical,	  and	  chemical	  
stimuli.	   When	   VSMCs	   are	   mechanically	   stimulated	   by	   stretching,	   they	   reflexively	  
contract.	  When	  VSMC	  membranes	  experience	  a	  voltage	  drop,	  L-­‐‑type	  calcium	  channels	  
open	  to	  increase	  intracellular	  calcium,	  which	  leads	  to	  VSMC	  contraction.	  VSMCs	  also	  
contract	   in	   response	   to	   a	   number	   of	   chemical	   stimuli	   such	   as	   angiotensin	   II,	  
norepinephrine,	  vasopressin,	  endothelin-­‐‑1	  and	  thromboxane	  A2	  (Khalil	  2010).	  
The	  mechanism	  by	  which	  smooth	  muscle	  contracts	  essentially	  begins	  with	  a	  
signal	   that	   causes	   a	   rise	   in	   intracellular	   calcium.	   Calcium	   immediately	   binds	  
calmodulin,	   forming	   the	   calcium-­‐‑calmodulin	   complex	   (Webb	   2003).	   	   The	   calcium-­‐‑
calmodulin	   complex	   activates	   myosin	   light	   chain	   kinase,	   which	   in	   turn,	  
phosphorylates	   and	   activates	  myosin.	   Activated	  myosin	   forms	   an	   ionic	   bond	  with	  
actin,	  contracts	  its	  head	  and	  finally	  breaks	  the	  bond	  with	  actin	  in	  a	  cyclical	  manner	  
using	  ATP	  as	  an	  energy	  source.	  	  The	  cycle	  of	  actin-­‐‑mysoin	  binding	  effectively	  shortens	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the	   combined	   length	   of	   both	   contractile	   proteins,	   resulting	   in	   smooth	   muscle	  
contraction	  (Webb	  2003).	  	  
When	  total	  calcium	  is	  depleted,	  actin-­‐‑myosin	  binding	  is	  unable	  to	  proceed	  due	  
to	  deactivation	  of	  the	  myosin	  head.	  This	  leads	  to	  the	  expansion	  of	  the	  combined	  actin-­‐‑
myosin	  length,	  resulting	  in	  smooth	  muscle	  relaxation	  (Sanders	  2008).	  
VSMCs	  are	  a	  heterogenous	  population	  in	  the	  vasculature	  and	  consist	  of	  two	  
morphologically	  distinct	   phenotypes:	  contractile	   and	  synthetic	   (Cecchettini	   et	   al.	  
2011).	  Contractile	  VSMCs	  are	  elongated,	  and	  spindle-­‐‑shaped	  cells.	  They	  do	  not	  divide	  
or	   migrate,	   and	   they	   are	   designated	   “quiescent”.	   Contractile	   VSMCs	   up-­‐‑regulate	  
expression	  of	  specific	  markers	  such	  as	  SMC	  α-­‐‑actin,	  SM22α,	  SMC	  myosin	  heavy	  chain	  
11	   and	   calponin.	   Synthetic	   VSMCs	   have	   a	   shorter,	   cobblestone	   morphology	   and	  
exhibit	  higher	  proliferative	  and	  synthetic	  capacity.	  VSMCs	  may	  share	  features	  of	  both	  
contractile	  and	  synthetic	  phenotypes	  (Rensen,	  Doevendans,	  and	  van	  Eys	  2007).	  
During	  embryonic	  development,	  VSMCs	  originate	   from	  a	  variety	  of	   sources.	  
VSMCs	  from	  aortic	  and	  pulmonary	  vessels	  are	  thought	  to	  originate	  from	  neural	  crest	  
cells	   of	   the	   ectoderm.	   Other	   VSMCs	   are	   derived	   from	   mesenchymal	   cells	   of	   the	  
mesoderm.	   The	   difference	   in	   a	   VSMC’s	   origin	   will	   inevitably	   result	   in	   varied	  
physiological	  behavior	  in	  response	  to	  stimuli.	  
	  
VSMC	  Proliferation	  and	  Differentiation	  	  
It	   has	   been	   accepted	   for	   at	   least	   fifty	   years	   that	   following	   injury,	   fully	  
differentiated,	  contractile	  type	  VSMCs	  de-­‐‑differentiate	  (Figure	  1),	  or	  regain	  features	  
of	   their	   synthetic	   progenitors	   (Buck	   1961;	   Nguyen	   et	   al.	   2013).	   These	   synthetic	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smooth	  muscle	  cells	  proliferate	  and	  secrete	  extracellular	  matrix.	  Upon	  repairing	  the	  
wound,	  VSMCs	  return	  to	  the	  differentiated	  contractile	  phenotype	  (Cecchettini	  et	  al.	  
2011;	  Chamley-­‐‑Campbell,	  Campbell,	  and	  Ross	  1979).	  	  
	  
	  
However	  recent	  findings	  have	  challenged	  this	  notion	  and	  suggest	  the	  existence	  
of	  a	  subpopulation	  of	  VSMCs	  within	  the	  tunica	  media	  labeled	  multivascular	  stem	  cells	  
(MVSMCs).	  MVSMCs	  express	  stem	  cell	  markers	  sca1,	  c-­‐‑kit	  and	  CD34.	  After	  an	  injury,	  
the	  expression	  of	  these	  stem	  cell	  markers	  significantly	  increase.	  MVSMCs	  proliferate	  
and	  later	  differentiate	  into	  contractile	  type	  smooth	  muscle	  cells	  following	  reparation	  
of	  the	  injury	  (Orlandi	  2015;	  Tang	  et	  al.	  2012).	  Hence	  the	  new	  hypothesis	  rejects	  the	  
idea	  that	  contractile	  smooth	  muscle	  cells	  de-­‐‑differentiate,	  and	  become	  proliferative.	  
MVSMCs	  have	  been	  shown	  to	  proliferate	  in	  response	  to	  vascular	  growth	  factors	  such	  
as	  fibroblast	  growth	  factor	  (FGF)	  and	  platelet	  derived	  growth	  factors-­‐‑BB	  (PDGF-­‐‑BB).	  
Since	  MVSMCs	  are	  the	  primary	  cells	  that	  differentiate	  in	  the	  event	  of	  vascular	  injury	  
and	   inflammation,	   they	   may	   play	   an	   important	   role	   in	   the	   pathogenesis	   of	  
	  
Figure	  1.	  Dedifferentiaton	  of	  VSMCs.	  	  
Quiescent	  contractile	  VSMCs	  dedifferentiate	  to	  become	  proliferative	  form	  called	  “synthetic”	  VSMCs.	  
A.	   B.	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atherosclerosis	   (Orlandi	   2015).	   These	   findings	   have	   been	   challenged	   and	   remain	  
controversial	  (Nguyen	  et	  al.	  2013).	  	  
	   TGF-­‐‑β	   is	   a	   cytokine	   that	   promotes	   VSMC	   differentiation	   into	   a	   contractile	  
phenotype	  (Rensen	  et	  al.	  2007).	  The	  mechanism	  by	  which	  TGF-­‐‑β	  elicits	  this	  response	  
is	  through	  the	  activation	  of	  KLF4	  by	  means	  of	  p38	  MAPK	  signaling	  pathway	  and	  Smad	  
proteins	   (Li	   et	   al.	   2010).	   In	   neural	   crest	   cells,	   TGF-­‐‑β	   causes	   SMC	   differentiation	  
through	  the	  activation	  of	  calcineurin	  (Mann	  et	  al.	  2004).	  Contrary	  to	  previous	  reports,	  
a	   more	   recent	   finding	   suggests	   that	   TGF-­‐‑β	   causes	   VSMC	   proliferation	   instead	   of	  
growth	  arrest	   through	  Smad3/ERK	  pathway	  (Pasithorn	  A.	  Suwanabol	  et	  al.	  2012).	  
The	  controversy	  behind	  TGF-­‐‑β’s	  effect	  on	  VSMCs	  underscores	  the	  need	  to	  revisit	  and	  
verify	  the	  role	  of	  important	  growth	  factor	  upon	  VSMCs.	  
Platelet	   Derived	   Growth	   Factor	   (PDGF)	   is	   a	   cytokine	   that	   promotes	   VSMC	  
differentiation	  into	  a	  synthetic	  phenotype.	  It	  is	  a	  dimeric	  protein	  containing	  disulfide-­‐‑
bonded	  A	  and	  B	  polypeptide	  chains	  (Zhao	  et	  al.	  2011).	  	  There	  are	  three	  types	  of	  PDGF	  
dimers:	  AA,	  AB,	  and	  BB.	  Among	  these	  dimers,	  PDGF	  BB	  is	  the	  most	  mitogenic.	  PDGF	  
binds	  and	  dimerizes	  its	  phospho-­‐‑tyrosine	  receptors	  α	  and	  β	  leading	  to	  activation	  of	  
major	  intracellular	  signaling	  pathways	  such	  as	  extracellular-­‐‑regulated	  protein	  kinase	  
(ERK)	   1/2	   and	   p38	  MAP	   kinase.	   	   Activation	   of	   these	   signaling	   pathways	   leads	   to	  
downregulation	   of	  α-­‐‑SMC	   actin,	  morphological	   shift	   to	   a	   synthetic	   phenotype	   and	  
increased	  proliferation	  and	  migration	  (Deguchi	  et	  al.	  1999;	  Hao	  et	  al.	  2002;	  Li	  et	  al.	  
1997;	  Nelson	  et	  al.	  1998).	  	  
	   Differentiation	   of	   VSMCs	   into	   a	   contractile	   phenotype	   is	   accompanied	   by	  
expression	  of	  specific	  markers	  such	  as	  SMC	  α-­‐‑actin,	  SM22α,	  SMC	  myosin	  heavy	  chain	  
	   17	  
11,	   and	   calponin.	   The	   morphing	   of	   VMSCs	   between	   synthetic	   and	   contractile	  
phenotype	   appears	   to	   be	   under	   the	   transcriptional	   control	   of	   the	   protein	   KLF4	  
(Zheng,	  Han,	  and	  Wen	  2010).	  	  In	  a	  rodent	  model,	  KLF4	  expression	  is	  elevated	  after	  
injury,	  peaking	  at	  2	  hours	  and	  returning	  to	  baseline	  within	  24	  hrs	  (Zheng	  et	  al.	  2010).	  
There	   is	  no	  consensus	  on	   the	  exact	  nature	  of	   the	  contribution	  of	  KLF4	  toward	   the	  
differentiation	  of	  VSMCs.	  	  
Evidence	  from	  the	  literature	  indicates	  two	  opposing	  roles	  for	  KLF4	  in	  VMSC	  
function:	  1.	  KLF4	  causes	  VSMCs	  to	  become	  more	  differentiated	  and	  thus,	  promotes	  a	  
contractile	   phenotype,	   or	   2.	   KLF4	   causes	   VSMCs	   to	   become	   less	   differentiated,	  
promoting	  a	  more	  synthetic	  phenotype	  (Gomez	  and	  Owens	  2012;	  Zheng	  et	  al.	  2010).	  
Owens	   et	   al.	   (2013),	   reported	   that	   KLF4	   is	   a	   transcriptional	   repressor	   of	   SMC	  
differentiation	   markers	   including	   SMC	   α-­‐‑actin,	   SM	   22α,	   and	   SM-­‐‑MHC	   by	   direct	  
interaction	  with	  promoter	  and	  repressor	  sequences	  of	  each	  of	   the	  contractile	  SMC	  
proteins.	  	  Conversely,	  Wen	  et	  al.	  (2010)	  reported	  that	  overexpressing	  KLF4	  causes	  an	  
increase	  in	  SM	  22α,	  and	  SMC	  α-­‐‑actin	  while	  silencing	  of	  KLF4	  using	  siRNA	  resulted	  in	  
attenuation	   of	   all-­‐‑trans-­‐‑retinoic-­‐‑acid	   induced	   contractile	   protein	   expression.	   	   In	  
support	  of	  these	  findings,	  Wassmann	  et	  al.	  (2007)	  found	  that	  KLF4	  increases	  SM	  22α	  
expression.	  
	   The	  dissension	  regarding	  the	  role	  of	  KLF4	  toward	  VSMC	  differentiation	  is	  far	  
from	  resolved.	  It	  is	  possible	  that	  the	  experimental	  conditions	  used	  in	  each	  laboratory	  
may	  be	  ignoring	  a	  key	  variable	  that	  could	  explain	  the	  differing	  results.	  What	  we	  can	  
conclude	  from	  these	  studies	  is	  that	  KLF4	  is	  an	  important	  protein	  that	  determines	  the	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VSMC	   differentiation	   state	   and	   warrants	   continued	   investigation	   to	   decode	   its	  
mechanism	  of	  action.	  	  
	  
	  
VSMC	  Primary	  Culture	  Techniques	  
	   VSMCs	  can	  be	  cultured	  from	  vascular	  tissue	  using	  two	  main	  methods:	  enzyme	  
dispersion	  or	  culturing	  of	  explants.	  Proper	  preparation	  and	  storage	  of	  blood	  vessels	  
is	   important	   for	   recovering	   the	   maximum	   number	   of	   viable	   cells	   for	   cell	   culture	  
(Proudfoot	  and	  Shanahan	  2012).	  	  
	  The	  enzyme	  dispersion	  of	  VSMCs	  from	  tissue	  is	  done	  by	  sectioning	  an	  aorta	  
and	   placing	   those	   sections	   in	   a	   serum-­‐‑free	   (DMEM	   containing	   5%	  
penicillin/streptomycin)	  digestion	  medium.	  After	  an	  overnight	   incubation	  at	  37°C,	  
cells	  are	  washed	  by	  centrifugation	  and	  placed	  in	  VSMC	  culturing	  medium.	  The	  explant	  
method	  begins	  with	  the	  distribution	  of	  sectioned	  pieces	  of	  aorta	  directly	  into	  a	  75cm2	  
flask	   containing	   VSMC	   culture	   medium,	   then	   the	   flask	   is	   incubated	   at	   37°C	   and	  
monitored	  for	  the	  outgrowth	  of	  VSMCs	  over	  the	  course	  of	  2-­‐‑3	  weeks.	  	  
	   The	  explant	  method	  relies	  heavily	  on	  cells	  that	  are	  able	  to	  switch	  to	  a	  synthetic	  
phenotype	  to	  proliferate	  and	  migrate	  thus	  inadvertently	  selects	  for	  cells	  that	  are	  able	  
to	  migrate.	  The	  benefit	  of	  the	  enzyme	  digestion	  is	  that	  all	  cells	  from	  the	  tunica	  media	  
gain	   an	   equal	   chance	   to	   become	   cultured.	   However,	   the	   explant	   method	   yields	   a	  
higher	   number	   of	   viable	   cells	   for	   tissue	   culture	   (Chamley-­‐‑Campbell	   et	   al.	   1979).	  
Growth	  of	  VSMCs	  can	  be	  encouraged	  and	  selected	  for	  by	  the	  addition	  of	  a	  number	  
growth	  factors.	  The	  addition	  of	  fibroblast	  growth	  factor	  (5	  ng/mL),	  Insulin	  (5	  ug/mL),	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ascorbic	  acid	  (50	  ug/mL),	  and	  epidermal	  growth	  factor	  (5	  ng/mL)	  will	  significantly	  
accelerate	   the	   outgrowth	   of	   VSMCs	   and	   maintain	   their	   proliferative	   (synthetic)	  
phenotype	  (Bourcier,	  Dockter,	  and	  Hassid	  1995;	  Millette	  et	  al.	  2006;	  Singh	  et	  al.	  2015;	  
Zhao	  et	  al.	  2011).	  
In	  our	  lab,	  sections	  of	  human	  aorta	  tissue	  is	  received,	  it	  is	  washed	  in	  serum-­‐‑
free	   medium	   (DMEM	   containing	   5%	   penicillin/streptomycin)	   and	   cut	   open	  
longitudinally	  using	  sterile	  forceps,	  and	  scissors.	  Although	  it	  is	  recommended	  that	  the	  
endothelial	  layer	  be	  removed,	  this	  is	  not	  necessary	  when	  using	  VSMC	  specific	  growth	  
factors	  while	  culturing.	  	  The	  aorta	  is	  sectioned	  into	  2	  cm	  x	  2	  cm	  pieces	  and	  placed	  in	  
culture	   treated	   75cm2	   flasks	   containing	   complete	   SMCM	   media	   (Science	   Cell,	  
Carlsbad,	   CA)	   containing	   10%	   FBS,	   4mM	   of	   L-­‐‑glutamine,	   and	   5%	  
penicillin/streptomycin	  (Figure	  2).	  	  
Proper	  control	  of	  the	  primary	  VSMC	  culture	  necessitates	  regularly	  monitoring	  
them	  for	  the	  expression	  of	  VSMC	  specific	  proteins	  such	  as	  SMC	  α-­‐‑actin,	  SM22a,	  SM-­‐‑
MHC,	  and	  calponin	  (Chamley-­‐‑Campbell	  et	  al.	  1979).	  Our	  primary	  VSMCs	  show	  proper	  
expression	  of	  SMC	  α-­‐‑actin,	  SMMHC	  (Figure	  3).	  We	  observed	  that	  the	  expression	  of	  
calponin	  is	  minimal	  in	  our	  primary	  VSMC	  cultures	  but	  increases	  as	  the	  cells	  undergo	  
increasing	   number	   of	   passages,	   suggesting	   that	   the	   cells	   are	   synthetic	   in	   earlier	  
passages	  but	  a	  more	  differentiated	  phenotype	   is	  being	  established	  with	  time,	  even	  





















Figure	  2.	  	  Culturing	  Vascular	  Smooth	  Muscle	  Cells.	  
Primary	  Vascular	  Smooth	  Muscle	  Cells	  were	  grown	  from	  aortic	  explants	  from	  deceased	  human	  
donors.	   Segments	  of	  descending	   thoracic	  or	   abdominal	   aortae	   from	  deceased	  human	  donors	  
were	   washed	   in	   PBS	   and	   fibrous	   adventitia	   were	   thoroughly	   removed.	   They	   were	   further	  
sectioned	  into	  2cm	  x	  2cm	  pieces	  and	  placed	  in	  culture	  treated	  75cm2	  flasks	  containing	  complete	  
SMCM	  media	  (ScienceCell,	  Carlsbad,	  CA)	  which	  selectively	  promotes	  the	  proliferation	  of	  VSMCs.	  
Media	  was	  changed	  every	  3-­‐‑4	  days.	  VSMC	  outgrowth	  from	  sectioned	  explants	  were	  observed	  on	  
average	  between	  7-­‐‑10	  days.	  	  
	  










Figure	  3.	  Primary	  VSMCs	  express	  Smooth	  Muscle	  α-­‐‑actin,	  Myosin	  Heavy	  Chain,	  and	  Calponin.	  
(A)	  Immunoflourescence	  image	  of	  VSMC	  stained	  with	  α-­‐‑SMC-­‐‑actin	  and	  visualized	  using	  Alexa	  Flour	  
488	  conjugated	  secondary	  antibody.	  Image	  was	  captured	  at	  60x	  magnification	  using	  the	  EVOS	  FL	  
imaging	   system.	   (B)	   Rabbit	   IgG	   isotype	   control	   for	   A	   and	   C.	   Image	   was	   captured	   at	   60x	  
magnification	  using	  the	  EVOS	  FL	  imaging	  system	  (C)	  VSMCs	  stained	  with	  Smooth	  Muscle	  Myosin	  
Heavy	   Chain	   and	   visualized	   using	   Alexa	   Flour	   488	   conjugated	   secondary	   antibody.	   Image	  was	  
captured	  at	  20x	  magnification	  using	  the	  EVOS	  FL	  imaging	  system	  (D)	  Total	  protein	  was	  collected	  
from	  samples	  of	  primary	  VSMC	  cultures	  at	  various	  passage	  numbers	  over	  the	  course	  of	  7	  weeks	  
averaging	  2	  passages	  per	  week.	  Proteins	  were	  fractionated	  by	  SDS-­‐‑Page	  using	  a	  4-­‐‑12%	  gradient	  
Polyacrylamide	  gel	  and	  transferred	  to	  a	  PVDF	  membrane.	  The	  membrane	  was	  probed	  with	  an	  anti-­‐‑
calponin	  antibody,	  followed	  by	  a	  secondary	  antibody	  conjugated	  to	  HRP.	  The	  membrane	  was	  later	  
visualized	  using	  an	  ECL	  substrate	  and	  ChemiDoc	  MP	  imaging	  system.	  	  	  
	  
Calponin 
    1            4            10          14         Passage	  #:
A.	  α	  SMC-­‐‑actin	  
C.	  Smooth	  Muscle	  Myosin	  
Heavy	  Chain	  
B.	  Isotype	  Control	  
D.	  






IL-­‐‑2	  PROMOTES	  VASCULAR	  SMOOTH	  MUSCLE	  PROLIFERATION	  
Interleukin-­‐‑2	  Physiology	  
Interleukin-­‐‑2	   (IL-­‐‑2)	   is	   a	   15.5	   kDa	   glycosylated	   type	   1	   cytokine	   initially	  
discovered	  due	  to	  its	  potent	  proliferative	  inducing	  activity	  for	  T-­‐‑cells	  	  (Ju	  et	  al.	  1987;	  
Morgan	  et	  al.	  1976).	  Since	  its	  discovery,	  IL-­‐‑2	  has	  been	  observed	  to	  exert	  numerous	  
and	  diverse	  functions	  within	  the	  immune	  system	  including	  the	  promotion	  of	  antibody	  
production	  (Mingari	  et	  al.,	  1984),	  aiding	  activation-­‐‑induced	  cell	  death	  (Lenardo	  et	  al.,	  
1999),	  and	  maintaining	  peripheral	  tolerance	  (Cote-­‐‑Sierra	  et	  al.,	  2004).	  	  
Interleukin-­‐‑2	  is	  secreted	  primarily	  by	  lymphoid	  cells:	  T-­‐‑cells	  (CD4+	  and	  CD8+),	  
B-­‐‑cells,	  NK	  cells,	  NKT	  cells,	  dendritic	  cells,	  and	  mast	  cells	  (Boyman	  and	  Sprent	  2012).	  
At	  resting	  conditions	  however,	  CD4+	  T-­‐‑cells	  appear	  to	  be	  the	  primary	  source	  of	  basal	  
level	   IL-­‐‑2	   production	   (Luckheeram	   et	   al.	   2012).	   Furthermore,	   activated	   CD4+	   and	  
CD8+	  T-­‐‑cells,	   sharply	   increase	   their	   IL-­‐‑2	  production	  and	  proliferate	   in	   response	   to	  
their	  own	  extracellular	  IL-­‐‑2	  in	  an	  autocrine	  manner	  (Arenas-­‐‑ramirez,	  Woytschak,	  and	  
Boyman	  2015).	  	  	  	  
IL-­‐‑2	   is	  known	  to	   induce	   the	  proliferation	  and	  migration	  of	  various	   immune	  
cells,	  particularly,	  natural	  killer	  (NK)	  cells,	  B	  cells	  and	  T-­‐‑regulatory	  cells	  (Liao	  et	  al.	  
2013).	  More	  recent	  findings	  suggest	  that	  IL-­‐‑2	  promotes	  the	  differentiation	  of	  some	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cells,	   such	   as	   the	   T	   helper	   1	   (Th1)	   and	   T	   helper	   2	   (Th2)	   cells,	   but	   inhibits	   the	  
development	  of	  others	  such	  as	  Th17	  and	  T-­‐‑follicular	  helper	  cells	  (Ballesteros-­‐‑Tato	  et	  
al.	   2012;	  Cote-­‐‑Sierra	   et	   al.	   2004;	  Liao,	   J.-­‐‑X.	   Lin,	   and	  Leonard	  2011).	  With	   so	  many	  
diverse	   functions,	   it	   is	   unlikely	   that	   we	   have	   fully	   grasped	   the	   breadth	   of	   IL-­‐‑2’s	  
influence	  on	  human	  physiology.	  
Previously	  our	  laboratory	  reported	  the	  finding	  of	  heparan-­‐‑sulfate	  bound	  IL-­‐‑2	  
deposited	  within	  the	  tunica	  media,	  a	  region	  rich	  in	  smooth	  muscle	  cells	  (Figure	  4.).	  	  
When	  IL-­‐‑2	  from	  the	  extracellular	  matrix	  of	  the	  vasculature	  was	  analyzed	  by	  western	  
blot,	  a	  band	  at	  the	  expected	  size	  of	  15kD	  was	  visible.	  However,	  the	  majority	  of	  the	  
signal	  came	  from	  bands	  that	  were	  at	  sizes	  that	  were	  multiples	  of	  15:	  45kd,	  75kD,	  90kD	  
(Figure	  5).	  Due	  to	  the	  abundance	  of	  transglutaminase	  in	  the	  extracellular	  matrix	  and	  
secretion	  of	   transglutaminase	  by	  VSMC	  (Johnson,	  Polewski,	   and	  Terkeltaub	  2008),	  
and	  previous	  reports	  demonstrating	   that	   transglutaminase	  cross-­‐‑links	   IL-­‐‑2	   in	  vivo	  
(Eitan	  and	  Schwartz	  1993),	  we	  believed	  that	  transglutaminase	  can	  cross-­‐‑link	  IL-­‐‑2	  in	  
vitro.	  When	  recombinant	  IL-­‐‑2	  was	  combined	  with	  transglutaminse	  in	  vitro,	  we	  were	  
able	   to	   show	   that	   transglutaminase	  was	   able	   to	   recreate	   the	   IL-­‐‑2	  banding	  pattern	  
observed	  from	  the	  protein	  extracts	  from	  sectioned	  aorta	  (Figure	  6).	  	  	  
VSMCs	  express	  the	  β	  and	  γ	  components	  of	  the	  IL-­‐‑2	  receptor	  (Hofbauer	  et	  al.	  
2006;	  Hocke	  et	  al.	  2007),	  thus	  it	   is	   likely	  that	  IL-­‐‑2	  interacts	  with	  VSMCs.	  The	  most	  
dominant	  and	  well	  characterized	  functions	  of	  IL-­‐‑2	  are	  proliferation	  and	  migration	  of	  
lymphoid	  cells	  (Liao,	  J.	  X.	  Lin,	  et	  al.	  2011).	  Therefore,	  we	  began	  our	  investigation	  by	  
evaluating	  the	  capacity	  for	  IL-­‐‑2	  to	  cause	  VSMC	  proliferation	  and	  migration.	  Survival	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signals	  activated	  by	  IL-­‐‑2	  in	  lymphocytes	  are	  well	  characterized	  (Liao	  et	  al.	  2013)	  and	  














Figure	  4.	  IL-­‐‑2	  is	  present	  in	  human	  blood	  vessel	  walls.	  
(A)	   A	   diagram	   of	   the	   aorta	   and	   the	   various	   layers	   present	   within.	   (B)	   Sections	   of	   human	   iliac	   artery	   were	   labeled	   with	  
antibodies	  recognizing	  IL-­‐‑2	  (TRITC)	  and,	   in	  FITC,	  either	  antibodies	  recognizing	  actin	  (smooth	  muscle	  cells),	   the	   lectin	  UEA	  
(endothelial	  cells),	  or	  anti-­‐‑perlecan	  antibodies,	  then	  assessed	  by	  confocal	  microscopy.	  Areas	  of	  co-­‐‑localization	  are	  evident	  in	  
yellow.	   Isotype	   controls	   were	   negative	   (not	   shown).	   Confocal	   images	   were	   generated	   using	   a	   Zeiss	   510	   Meta	   confocal	  
microscope	  utilizing	  AIM	  software.	  (C)	  Sections	  of	  human	  iliac	  artery	  were	  stained	  with	  an	  anti-­‐‑human	  IL-­‐‑2	  antibody	  (TRITC)	  
in	  the	  presence	  (“pre-­‐‑adsorbed	  IL-­‐‑2”)	  or	  absence	  (“IL-­‐‑2”)	  of	  pre-­‐‑incubation	  with	  a	  5µM	  excess	  of	  human	  IL-­‐‑2.	  In	  Figure	  b,	  the	  
green	  color	  originates	  from	  autofluorescence	  at	  488	  nm	  of	  elastin	  fibers	  within	  the	  internal	  and	  external	  elastic	  laminae.	  Miller,	  
J.	  D.,	  Stevens,	  E.	  T.,	  Smith,	  D.	  R.,	  Wight,	  T.	  N.,	  &	  Wrenshall,	  L.	  E.	  (2008).	  Perlecan:	  a	  major	  IL-­‐‑2-­‐‑binding	  proteoglycan	  in	  murine	  
spleen.	  Immunology	  and	  cell	  biology,	  86(2),	  192-­‐‑199.	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Figure	  5.	  IL-­‐‑2	  administered	  intravenously	  accumulates	  in	  the	  ECM	  of	  the	  murine	  aorta.	  	  
Balb/c	  mice	  were	  given	  1	  μg	  of	  infrared	  dye-­‐‑conjugated	  IL-­‐‑2	  daily	  by	  intraperitoneal	  injection	  for	  8	  doses,	  
and	  sacrificed	  3	  days	   following	  the	  last	  dose.	  Tissues	  were	  lysed	  and	  fractionated	  by	  SDS-­‐‑PAGE	  in	  a	  10%	  
polyacrylamide	   gel.	   Proteins	  were	   transferred	   to	   nitrocellulose	  membrane	   and	   analyzed	   on	   an	   Odyssey	  
infra-­‐‑red	  scanner.	  Results	  shown	  are	  representative	  of	  10	  experiments.	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Figure	  6.	  (A)	  IL-­‐‑2	  is	  found	  in	  human	  aorta	  as	  monomeric	  and	  multimeric	  forms.	  Human	  aortic	  explants	  
1	   cm	   x1	   cm	   were	   washed	   in	   500	   uL	   of	   a	   buffer	   composed	   of	   0.5	   M	   NaCl,	   10	   mM	   tris,	   pH	   7.5	  
supplemented	  with	  proteinase	  and	  phosphatase	  inhibitor	  mixtures	  (Sigma-­‐‑Aldrich,	  )	  and	  25	  mM	  EDTA	  
overnight	  at	  4°C.	  The	  explant	  was	  removed	  and	  the	  remaining	  wash	  buffer	  was	  fractionated	  by	  SDS-­‐‑
PAGE	   and	   transferred	   to	   a	   nitrocellulose	   membrane.	   The	   membrane	   was	   probed	   with	   anti-­‐‑IL-­‐‑2	  
antibody	   and	   visualized	   using	   a	   HRP	   conjugated	   secondary	   antibody	   and	   an	   ECL	   substrate.	   (B)	  
transglutaminase	   cross-­‐‑links	   IL-­‐‑2	   forming	   IL-­‐‑2	   multimers.	   10µg	   of	   IL-­‐‑2	   suspended	   in	   TBS	   was	  
incubated	  with	  or	  without	  5mU/mL	  of	  transglutaminase	  for	  1hr.	  at	  37°C.	  The	  reactions	  were	  quenched	  
by	  the	  addition	  of	  laemmli	  buffer.	  The	  IL-­‐‑2	  proteins	  from	  the	  reaction	  were	  fractionated	  by	  SDS-­‐‑Page	  
using	  a	  12%	  polyacrylamide	  gel	  transferred	  to	  a	  nitrocellullose	  membrane,	  and	  probed	  with	  an	  anti-­‐‑
IL-­‐‑2	   antibody	   conjugated	   to	  HRP.	   The	  membrane	  was	   later	   visualized	   using	   an	   ECL	   substrate	   and	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IL-­‐‑2	   is	  detected	   in	  sections	  of	  abdominal	  aorta	  as	  an	  oligomer,	  possibly	  due	  to	  
transglutaminase	  (Figure	  5):	  
Human	  aortic	  explant	  1	  cm	  x	  1	  cm	  was	  washed	  in	  buffer	  composed	  of	  0.5	  M	  
NaCl,	   10	   mM	   Tris,	   pH	   7.5	   supplemented	   with	   proteinase/phosphatase	   inhibitor	  
mixtures	   (Sigma-­‐‑Aldrich)	   and	   25	   mM	   EDTA	   overnight	   at	   4°C.	   The	   explant	   was	  
removed	   and	   the	   remaining	   wash	   buffer	   was	   fractionated	   by	   SDS-­‐‑PAGE	   and	  
transferred	  to	  a	  nitrocellulose	  membrane.	  The	  membrane	  was	  probed	  with	  an	  anti-­‐‑
IL-­‐‑2	  antibody	  and	  visualized	  using	  a	  secondary	  antibody	  conjugated	  to	  HRP	  and	  an	  
ECL	  substrate.	  15	  kD	  band	  along	  with	  much	  more	  prominent	  bands	  at	  sizes	  that	  are	  
multiples	  of	  15	  were	  observed.	  We	  believe	  that	  these	  are	  IL-­‐‑2	  oligomers.	  	  
We	   suspected	   that	   the	   abundance	   of	   the	   cross-­‐‑linking	   enzyme	  
transglutaminase	   was	   responsible	   for	   the	   oligomerization	   of	   IL-­‐‑2	   within	   the	  
vasculature.	  Thus	  we	  tested	  the	  efficiency	  of	  transglutaminase	  in	  cross-­‐‑linking	  IL-­‐‑2	  
in-­‐‑vitro.	  10µg	  of	  IL-­‐‑2	  suspended	  in	  TBS	  was	  incubated	  with	  or	  without	  5	  mU/mL	  of	  
transglutaminase	  for	  1hr.	  at	  37°C.	  The	  reactions	  were	  quenched	  by	  the	  addition	  of	  
Laemmli	  buffer.	  The	  IL-­‐‑2	  proteins	  from	  the	  reaction	  were	  fractionated	  by	  SDS-­‐‑Page	  
using	   a	   12%	   polyacrylamide	   gel,	   transferred	   to	   a	   nitrocellullose	   membrane,	   and	  
probed	   with	   an	   anti-­‐‑IL-­‐‑2	   antibody	   conjugated	   to	   HRP.	   The	   membrane	   was	   later	  
visualized	   using	   an	   ECL	   substrate	   and	   ChemiDoc	   MP	   imaging	   system	   (Biorad,	  
Hercules,	   CA).	   The	   pattern	   of	   bands	   observed	   from	   the	   transglutaminase	   treated	  
sample	  of	  IL-­‐‑2	  was	  similar	  to	  the	  multimeric	  IL-­‐‑2	  bands	  observed	  from	  the	  protein	  
extracted	   from	   the	   extracellular	   matrix	   of	   human	   aorta.	   Our	   data	   suggests	   that	  
transglutaminase	   crosslinks	   IL-­‐‑2	   into	   multimers.	   Due	   to	   the	   abundance	   of	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transglutaminase	   in	   the	   extracellular	   matrix	   of	   the	   aorta,	   it	   is	   very	   likely	   that	  
transglutaminase	  could	  be	  a	  major	  factor	  in	  crosslinking	  IL-­‐‑2	  in	  vivo.	  	  
	  
IL-­‐‑2	  causes	  proliferation	  of	  cultured	  VSMCs	  (Figure	  7).	  	  
In	  order	  to	  test	  the	  proliferative	  capacity	  of	  primary	  VSMCs	  in	  response	  to	  IL-­‐‑
2,	   we	   synchronized	   the	   cells	   by	   serum	   starvation	   and	   treated	   them	   with	  
physiologically	  relevant	  doses	  of	  IL-­‐‑2.	  DNA	  synthesis	  was	  quantified	  in	  response	  to	  
IL-­‐‑2	  treatment	  using	  EDU	  incorporation	  and	  the	  Click-­‐‑iT	  Amplex®	  UltraRed	  assay	  kit.	  
VSMCs	  were	  plated	  in	  96	  well	  plates	  with	  complete	  DMEM	  media	  containing	  10%	  FBS.	  
After	  72	  hrs,	  the	  cells	  were	  washed	  in	  PBS	  and	  serum	  starved	  in	  DMEM	  for	  another	  
48	  hrs.	  The	  cells	  then	  were	  treated	  with	  either	  glycosylated	  or	  non-­‐‑glycosylated	  IL-­‐‑2	  
and	  EDU.	  VSMCs	  were	  incubated	  at	  37°C	  for	  96	  hrs.	  Click-­‐‑IT®	  assay	  was	  carried	  out	  
following	  manufacturer	  instructions	  (Life	  Technologies).	  The	  results	  show	  that	  DNA	  
synthesis	  was	  significantly	  elevated	  in	  VSMCs	  when	  treated	  with	  both	  glycosylated	  
and	  non-­‐‑glycosylated	  IL-­‐‑2	  (Figure	  7).	  	  
	  
IL-­‐‑2	  treatment	  of	  explants	  of	  the	  human	  aorta	  causes	  VSMC	  outgrowth	  (Figure	  8	  
&	  Figure	  9).	  	  
Human	  aortae	   from	  a	   total	  of	  6	  donors	  were	  washed	   in	  PBS,	   sectioned	  and	  
placed	  lumen	  side	  down	  into	  24	  well	  plates.	  300	  µL	  of	  DMEM	  containing	  0.5%	  FBS	  
was	  added	  to	  each	  well	  and	  designated	  wells	  were	  treated	  with	  either	  glycosylated	  or	  
non-­‐‑glycosylated	  IL-­‐‑2	  in	  triplicate.	  Culture	  media	  was	  replaced	  once	  every	  7	  days	  and	  
these	  plates	  were	  maintained	  for	  4-­‐‑6	  weeks.	  Bright-­‐‑field	  images	  of	  explants	  treated	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with	   IL-­‐‑2	   show	   cells	   emerging	   from	   the	   explants	   that	   morphologically	   resemble	  
smooth	  muscle	  cells.	  	  
	  The	  Alamar	  blue	  assay	  is	  designed	  to	  measure	  quantitatively	  the	  proliferation	  
of	  animal	  cells,	  bacteriae	  and	  fungi.	  Aortic	  explants	  were	  removed	  after	  4	  weeks	  and	  
the	  Alamar	  blue	  assay	  was	  used	  following	  manufacturer	  instructions	  (Thermofischer	  
Scientific)	  to	  quantify	  the	  emerging	  cells.	  The	  assay	  is	  a	  fluorometric	  REDOX	  indicator	  
proportionate	  to	  metabolic	  activity	  of	  cells.	  The	  numerical	  values	  were	  normalized	  to	  
control	  wells	  and	  graphed	  using	  a	  box	  and	  whiskers	  plot	  (Figure	  7,	  n=6).	  The	  results	  
indicate	  that	  there	  was	  a	  significant	  increase	  in	  the	  number	  of	  motile	  cells	  emerging	  
from	  explants	  of	  the	  human	  aorta	  when	  treated	  with	  IL-­‐‑2	  (p	  <	  0.05).	  	  
Cells	  that	  emerged	  from	  VSMCs	  were	  later	  lysed	  and	  probed	  with	  the	  VSMC	  
marker,	  α-­‐‑SMC	  actin,	  to	  confirm	  their	  identity	  as	  VSMCs	  using	  the	  western	  blotting	  
technique.	  Results	  show	  that	  cells	  emerging	  from	  IL-­‐‑2	  treated	  VSMCs	  are	  positive	  for	  
α-­‐‑SMC	  actin	  which	  sufficiently	  identifies	  them	  as	  VSMCs	  (Figure	  9,	  n=6).	  
Our	   data	   suggests	   that	   IL-­‐‑2	   is	   capable	   of	   inducing	   proliferation	   of	   vascular	  





































































) **p = 0.006
A. B. 
Figure	  7.	  IL-­‐‑2	  treatment	  causes	  increased	  DNA	  synthesis	  in	  VSMCs.	  	  
VSMCs	  were	  grown	  to	  ~30%	  confluence	  in	  96	  well	  plates	  supplemented	  with	  complete	  DMEM	  media.	  After	  
a	  48	  hr	  serum	  starvation	  period,	  designated	  wells	  were	   treated	  with	  either	  non-­‐‑glycosylated	   IL-­‐‑2	  (A)	  or	  
glycosylated	  IL-­‐‑2	  (B)	  and	  EDU	  (5-­‐‑ethynyl-­‐‑2´-­‐‑deoxyuridine)	  was	  added	  to	  all	  experimental	  wells	  at	  a	  final	  
concentration	   of	   20	   μM.	   After	   a	   48hr.	   Incubation,	   cells	   were	   fixed	   and	   permeabilized	   in	   4%	  
paraformaldehyde.	  CLICK-­‐‑IT	  EDU	  kit	   from	  Life-­‐‑Technologies	  was	  used	  to	  quantify	  EDU	  incorporation	  by	  
following	  manufacturer’s	   protocol.	   Fluorescence	   is	   directly	   correlated	  with	   EDU	   incorporation	   and	  was	  
measured	  by	  the	  Synergy	  H1	  plate	  reader	  (BioTEK,	  Winooski,	  VT).	  	  n=3	  
	  




Figure	  8.	  VSMCs	  emerge	  from	  human	  aortic	  explants	  when	  treated	  with	  IL-­‐‑2.	  	  
Segments	  of	  descending	  thoracic	  or	  abdominal	  aortae	  	  received	  from	  deceased	  human	  donors	  
were	   washed	   in	   PBS	   and	   fibrous	   adventitia	   were	   thoroughly	   removed.	   They	   were	   further	  
sectioned	  into	  2cmx2cm	  pieces	  and	  placed	  in	  24	  well	  plates	  containing	  DMEM	  and	  allowed	  to	  
incubate	   at	   37ºC	   for	   24hrs.	   Media	   was	   replaced	   with	   DMEM	   containing	   0.5%	   FBS	   and	  
designated	  wells	  received	  30ng/mL	  of	  glycosylated	  IL-­‐‑2	  or	  non-­‐‑glycosylated	  IL-­‐‑2.	  Alamar	  Blue	  
(Life	  Technologies)	  was	  used	  to	  measure	  relative	  cell	  number.	  
	  
	  

























Figure	  9.	  Cells	  emerging	  from	  explants	  treated	  with	  IL-­‐‑2	  express	  
α-­‐‑SMC	   Actin.	  Total	   lysates	   from	   cells	   emerging	   from	   IL-­‐‑2	   treated	  
explants	  were	  fractionated	  by	  SDS	  page	  using	  a	  10%	  polyacrylamide	  
gel.	  Proteins	  were	  transferred	  onto	  a	  PVDF	  membrane	  and	  probed	  
with	   antibodies	   against	   α-­‐‑SMC	   Actin	   followed	   by	   a	   secondary	  
antibody	   conjugated	   to	   HRP.	   The	   membrane	   was	   later	   visualized	  
using	  an	  ECL	  substrate	  and	  ChemiDoc	  MP	  imaging	  system	  (Biorad).	  
Strong	  band	  indicated	  by	  the	  arrow	  was	  observed	  at	   the	  predicted	  
size	  of	  42kDA	  in	  lysates	  from	  VSMCs	  emerging	  from	  both	  IL-­‐‑2	  treated	  
explants,	   as	   well	   as	   VSMCs	   emerging	   from	   positive	   control,	   SMC	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Summary	  &	  Discussion:	  
	   The	  most	  well	  characterized	  functions	  of	  IL-­‐‑2	  are	  to	  promote	  proliferation	  and	  
to	  elicit	  migration	  from	  lymphoid	  cells	  (Liao,	  J.	  X.	  Lin,	  et	  al.	  2011).	  IL-­‐‑2	  treatment	  of	  
primary	  VSMCs	  derived	  from	  the	  aorta	  of	  deceased	  donors	  produced	  a	  demonstrable	  
proliferative	  effect.	  Also,	  IL-­‐‑2	  treatment	  of	  sectioned	  abdominal	  aortae	  in	  vitro	  caused	  
significant	  VSMC	  outgrowth.	  Compiled	  data	   from	  aortic	   explants	   showed	   that	   IL-­‐‑2	  
significantly	  augments	  VSMC	  outgrowth.	  We	  did	  not	  however,	  observe	  any	  apparent	  
IL-­‐‑2	  mediated	  morphological	  changes	  in	  VSMCs.	  
The	  experimental	  conditions	  used	  to	  obtain	  these	  results	  have	  been	  developed	  
through	  a	  number	  of	  trials.	  Proliferation	  studies	  were	  conducted	  over	  a	  96	  hr	  time	  
frame	  in	  order	  to	  accommodate	  the	  48	  hr	  doubling	  time	  reported	  for	  cultured	  VSMCs	  
(Chamley-­‐‑Campbell	   et	   al.	   1979).	   In	   addition,	   VSMCs	   were	   serum	   starved	   to	  
synchronize	   them	  to	   the	  G0	  stage	  of	   cell	   cycle	  and	  48	  hrs	  of	   serum	  starvation	  was	  
empirically	  determined	  to	  be	  the	  most	  effective	  time	  for	  observing	  the	  maximal	  effect	  
of	   IL-­‐‑2	   on	   VSMCs.	   The	   literature	   is	   replete	   with	   proliferation	   studies	   that	   used	  
between	  0.1%-­‐‑1%	  of	  FBS,	  we	  chose	  to	  remove	  FBS	  entirely	  in	  order	  to	  avoid	  studying	  
the	  effects	  of	  IL-­‐‑2	  in	  combination	  with	  any	  unknown	  growth	  factors	  present	  in	  fetal	  
bovine	  serum.	  
	   Primary	   VSMCs	   in	   culture	   are	   a	   heterogenous	   population	   derived	   from	  
different	   embryonic	  origins.	  Thus	   every	   cell	  will	   not	   respond	   in	   the	   same	  manner	  
(Majesky	  2007).	  This	  presents	  a	  significant	  challenge	  to	  studying	  the	  effects	  of	  growth	  
factors	   on	   VSMCs.	   We	   addressed	   this	   concern	   by	   assessing	   IL-­‐‑2	   mediated	   VSMC	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proliferation	  upon	  VSMCs	  from	  multiple	  donors	  at	  a	  range	  of	  passage	  numbers.	  We	  
are	  therefore	  confident	  that	  our	  findings	  can	  be	  generalized	  to	  all	  VSMCs.	  	  
	   Since	  we	  know	  that	  VSMCs	  proliferate	   from	  explants	  of	   the	  human	  aorta	   in	  
response	   to	  growth	   factors	  such	  as	  FGF,	   insulin,	  and	  EGF,	  we	   tested	  explants	  with	  
varying	  concentrations	  of	  the	  glycosylated	  and	  non-­‐‑glycosylated	  IL-­‐‑2	  to	  assess	  for	  any	  
VSMC	  outgrowth.	  The	  benefit	  of	  using	  an	  explant	  is	  that	  we	  are	  not	  only	  observing	  the	  
response	   of	   VSMCs	   to	   IL-­‐‑2,	  we	   are	   recreating	   the	  microenvironment	   under	  which	  
VSMCs	  would	  normally	  encounter	  IL-­‐‑2.	  This	  microenvironment	  includes	  contact	  with	  
the	  extracellular	  matrix,	   contact	  with	  other	   resident	  cells	  of	   the	   tunica	  media,	   and	  
cytokines	  secreted	  from	  cells	  residing	  in	  the	  explant:	  endothelial	  cells,	  and	  fibroblasts.	  
When	   we	   compared	   the	   wells	   containing	   IL-­‐‑2	   treated	   and	   non-­‐‑treated	  
explants,	  we	   found	   a	   significantly	   higher	   number	   of	   cells	   emerging	   from	   explants	  
treated	  with	   IL-­‐‑2.	   These	   cells	  were	   elongated	   and	   spindle	   shaped,	   suggesting	   that	  
these	  were	  possible	  VSMCs.	  To	  confirm	  their	  identity	  to	  be	  VSMCs	  we	  quantified	  SMC-­‐‑
α	  actin	  expression	  in	  their	  lysates.	  	  
	   VSMC	  outgrowth	  from	  the	  explants	  treated	  with	  IL-­‐‑2	  did	  not	  yield	  a	  normal	  
dose	  response	  curve.	  IL-­‐‑2	  mediated	  outgrowth	  was	  prominent	  at	  30ng/mL	  but	  we	  
observed	   significantly	   less	   response	   at	   higher	  doses	   of	   IL-­‐‑2.	   This	   suggests	   a	  more	  
complicated	  interplay	  between	  IL-­‐‑2,	  VSMCs	  and	  the	  microenvironment	  created	  by	  the	  
presence	  of	  other	  cell	  types,	  such	  as	  endothelial	  cells	  and	  fibroblasts.	  	  





IL-­‐‑2	  Promotes	  Vascular	  Smooth	  Muscle	  Migration	  
VSMC	  Migration	  Physiology	  
Migration	  of	  VSMCs	  has	  been	  observed	  during	  vascular	  development,	  injury,	  
and	   atherogenesis.	   Vascular	   injuries	   commonly	   result	   from	   clinical	   interventions	  
such	  as	  angioplasty,	  vascular	  stent	  implantation,	  or	  organ	  transplantation	  (Gerthoffer	  
2007).	  During	  atherogenesis,	  VSMCs	  migrate	  from	  the	  tunica	  media	  into	  the	  tunica	  
intima	  of	  the	  vasculature	  of	  the	  developing	  plaque	  (Rudijanto	  2007).	  	  
VSMCs	   are	   surrounded	   and	   stabilized	   by	   the	   ECM,	   composed	   largely	   of	  
collagen	  (types	  I	  &	  III),	  elastin,	  and	  proteoglycans.	  VSMCs	  must	  undergo	  a	  series	  of	  
complex	   steps	   in	   order	   to	   migrate:	   (1)	   Overcome	   the	   physical	   barrier	   of	   the	  
extracellular	  matrix	   through	   secretion	   of	   degradative	   enzymes,	   (2)	   Rearrange	   the	  
cytoskeleton	   to	   protrude	   towards	   the	   intended	   direction	   of	   migration	   (3)	   Form	  
transient	   contacts	  with	   the	  ECM	   to	   create	   traction,	   (4)	  Use	   contractile	   proteins	   to	  
generate	  force	  by	  ATP	  hydrolysis	  (Gerthoffer	  2007).	  	  
Pro-­‐‑migratory	   cytokines	   exert	   their	   effects	   through	   the	   activation	   of	  
intracellular	  signaling	  proteins	  such	  as	  Phosphotidylinositol	  3	  Kinase	  (PI3K),	  MAPKs	  
(ERK1/2,	  p38),	  Protein	  Kinase-­‐‑C,	  and	  Focal	  Adhesion	  Kinase	  (FAK)	  (Huang,	  Jacobson,	  
and	  Schaller	  2004;	  Pribic	  and	  Brazill	  2012).	  These	  signals	  result	  in	  the	  upregulation	  
of	   MMP-­‐‑2	   and	   MMP-­‐‑9	   synthesis	   within	   VSMCs.	   MMPs	   are	   secreted	   by	   VSMCs	   to	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degrade	  the	  surrounding	  matrix,	   thereby	  untethering	  the	  VSMCs	  to	  become	  motile	  
(Cho,	  Graves,	  and	  Reidy	  2000).	  	  
To	   maintain	   forward	   motion,	   VSMCs	   must	   form	   focal	   contacts.	   Jagged	  
extensions	  of	  the	  cell	  membrane	  called	  lamellipodia	  form	  at	  the	  edge	  of	  the	  VSMCs	  
that	  is	  facing	  the	  source	  of	  pro-­‐‑migratory	  cytokines.	  The	  lamellipodia	  make	  adhesive	  
contacts	   with	   components	   of	   the	   ECM	   through	   VSMC	   surface	   integrin	   receptors.	  
These	  integrins	  form	  a	  strong	  link	  between	  the	  ECM	  and	  VSMC	  cytoskeleton	  called	  
focal	  contacts.	  The	   formation	  of	   focal	   contacts	  creates	  both	   traction	  and	  generates	  
intracellular	  signaling	  that	  promotes	  actin	  polymerization.	  Meanwhile,	  degradation	  
of	  these	  focal	  contacts	  at	  the	  trailing	  edge	  is	  equally	  important	  for	  the	  cell	  to	  move	  
forward	  unfettered	  (Gerthoffer	  2007).	  
Proteins	  assembling	  intracellularly	  to	  form	  focal	  contacts	  are	  focal	  adhesion	  
kinase	   (FAK),	   vinculin,	   paxillin,	   tensin,	   p130cas,	   and	   Src.	   During	   migration,	   these	  
components	  become	  activated	  at	  the	  leading	  edge	  by	  phosphorylation	  through	  pro-­‐‑
migratory	  intracellular	  signaling	  pathways.	  These	  components	  are	  deactivated	  at	  the	  
trailing	  edge	  by	  inhibitory	  signaling	  delivered	  by	  MTOC	  extensions(Gerthoffer	  2007).	  	  
The	   cellular	   polarization	   of	   the	   actin	   polymerization	   and	   depolymerization	  
cycle	  is	  the	  primary	  means	  of	  re-­‐‑shaping	  the	  leading	  edge	  to	  protrude	  and	  form	  the	  
framework	  necessary	  for	  the	  assembly	  of	  contractile	  machinery.	  It	  is	  defined	  by	  the	  
process	  of	  converting	  globular,	  free	  actin	  into	  long	  filaments.	  This	  process	  is	  regulated	  
by	   actin	   binding	   proteins	   that	   are	   activated	   by	   intracellular	   signaling	   pathways	  
triggered	  by	  pro-­‐‑migratory	  cytokines.	  Actin	  depolarization	  is	  controlled	  by	  gelsolin	  
and	   cofilin.	   The	   presence	   of	   calcium	   causes	   gelsolin	   to	   degrade	   actin	   while	   the	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presence	  of	  PIP2	  causes	  gelsolin	  to	  dissociate	  from	  the	  actin	  filaments	  allowing	  for	  
actin	   polymerization	   (Gardel	   et	   al.	   2010;	   Vicente-­‐‑Manzanares,	   Choi,	   and	   Horwitz	  
2009).	  	  
VSMC	  migration	  is	  initiated	  by	  the	  formation	  of	  cytokine	  gradients	  emanating	  
from	  the	  source	  of	  inflammation.	  The	  primary	  source	  of	  these	  cytokines	  within	  the	  
vasculature	  are	  endothelial	  cells,	  platelets,	  fibroblasts	  and	  immune	  cells	  (Zhang	  and	  
An	  2007).	   Currently,	   the	  most	  potent	   cytokines	   that	  promote	  VSMC	  migration	  are	  
PDGF,	  Endothelin-­‐‑1,	  Thrombin,	  Fibroblast	  Growth	  Factor	  (FGF),	  Interferon-­‐‑g	  (IFN-­‐‑g),	  
and	  IL-­‐‑1	  .	  	  
IL-­‐‑2	   is	  a	  potent	   chemotactic	   factor	   for	   lymphocytes.	  Lymphocytes	  activated	  
with	   PHA	   responded	   to	   an	   IL-­‐‑2	   gradient	   by	   migrating	   towards	   higher	   IL-­‐‑2	  
concentration	   (Kornfeld	   et	   al.	   2016;	   Pleass	   and	   Camp	   1994).	   Furthermore,	   IL-­‐‑2	  
treatment	   was	   shown	   to	   activate	   Pyk-­‐‑2	   and	   FAK2	   both	   of	   which	   are	   major	  
components	  to	  focal	  contacts	  needed	  for	  migration	  (Brockdorff	  et	  al.	  1998;	  Miyazaki	  
et	   al.	   1998).	   IL-­‐‑2	   mediated	   signaling	   supports	   cellular	   migration	   through	   the	  
activation	  of	  the	  MAPK	  pathway	  and	  the	  PI3K/AKT	  pathway	  (Discussed	  in	  Chapter	  
6).	  	  
Due	   to	   the	   presence	   of	   IL-­‐‑2	   receptor	   components	   on	   VSMCs	   and	   the	   co-­‐‑
localization	  of	  IL-­‐‑2	  and	  VSMCs	  in	  the	  tunica	  media,	  we	  asked	  the	  question,	  does	  IL-­‐‑2	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Quantifying	  Cell	  Migration	  
There	   are	   a	  number	  of	   assays	   available	   to	   assess	   the	  migratory	   capacity	  of	  
VSMCs.	   These	   methods	   either	   use	   imaging	   to	   capture	   cellular,	   disposition	   or	  
phenotype	   change	   or	   quantify	   movement	   through	   a	   membrane.	   Scratch	   wound	  
assays	   are	   the	   most	   common	   and	  most	   easily	   carried	   out.	   Scratch	   wound	   assays	  
capture	   cell	   movement	   after	   a	   portion	   of	   a	   confluent	   monolayer	   of	   VSMCs	   are	  
removed	  created	  a	  “wound.”	  The	  rate	  of	  wound	  closure	  is	  quantified	  with	  and	  without	  
treatment	   of	   a	   potential	   migratory	   or	   anti-­‐‑migratory	   factor.	   This	   assay	   is	   high-­‐‑
throughput	  and	  requires	  minimal	  purchase	  of	  additional	  equipment	  (Cory	  2011).	  
However,	  many	  growth	  factors	  require	  a	  growth	  factor	  gradient	  for	  optimal	  
migration.	  This	  can	  be	  achieved	  with	  a	  Boyden	  chamber	  assay.	  In	  this	  assay,	  culture	  
wells	  are	  divided	  into	  two	  chambers,	  a	   top	  chamber	  containing	  cells	  and	  a	  bottom	  
chamber	  containing	  the	  growth	  factors.	  For	  our	  studies,	  cultured	  smooth	  muscle	  cells	  
were	  plated	  on	  the	  top	  chamber,	  which	  contains	  pores	  (8-­‐‑10µm).	  A	  migratory	  factor	  
is	  added	  to	  the	  bottom	  chamber.	  Cells	  that	  migrate	  to	  the	  bottom	  surface	  are	  captured	  
in	   the	   pores.	   These	   cells	   are	   stained,	   counted,	   and	   the	   number	   of	   total	   cells	   is	  
compared	  between	  wells	  that	  received	  the	  treatment	  and	  control	  wells.	  This	  method	  
is	  much	  more	  sensitive	  than	  the	  scratch	  wound	  assay	  (Chen	  2005).	  	  
A	  Dunn	  chemotaxis	  chamber	  generates	  a	  long-­‐‑lasting	  gradient	  and	  allows	  for	  
phase	   contrast	   imaging	   that	   captures	   phenotype	   changes.	   This	   is	   the	   preferred	  
approach	  for	  VSMCs,	  but	  ideally	  requires	  time	  lapse	  photography	  and	  a	  temperature	  
controlled	   stage	   (Gerthoffer	   2007).	   	   Given	   the	   cost	   effectiveness	   and	   easy	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quantification	  of	  the	  Boyden	  chamber	  method,	  we	  chose	  this	  technique	  for	  our	  intitial	  
studies.	  	  
IL-­‐‑2	  causes	  migration	  of	  VSMCs	  (Figure	  10)	  
	   VSMCs	   maintained	   in	   complete	   SMCM	   containing	   smooth	   muscle	   growth	  
factors	  (Science	  Cell,	  Carlsbad,	  CA)	  were	  washed	  in	  PBS.	  The	  Boyden	  chamber	  assay	  
was	  done	  to	  asses	  VSMC	  migration.	  DMEM	  was	  added	  to	  both	  the	  upper	  and	  lower	  
chambers	   and	   2	   x	   104	   VSMCs	   were	   added	   to	   the	   upper	   chamber.	   The	   plate	   was	  
incubated	  for	  24	  hr	  at	  37˚C.	  Upper	  chamber	  media	  was	  replaced	  with	  DMEM	  while	  
lower	  chamber	  was	  replaced	  with	  DMEM	  containing	  30	  ng/mL	  of	  IL-­‐‑2	  or	  PDGF.	  After	  
8	  hr	  of	  incubation	  at	  37˚C,	  chambers	  were	  washed	  in	  PBS	  and	  fixed	  in	  methanol.	  Cells	  
were	  visualized	  using	  Sybr	  green.	  Captured	  fluorescent	  images	  were	  processed	  using	  
the	  image	  J	  software	  from	  NIH,	  which	  allowed	  for	  accurate	  cell	  counting.	  Results	  show	  
that	  Boyden	  chambers	  containing	  IL-­‐‑2	  treated	  VSMCs	  showed	  a	  significantly	  higher	  
number	  of	  cells	  migrating	  than	  untreated	  cells.	  PDGF	  treatment	  resulted	  in	  the	  most	  
number	  of	  cells	  migrating	  during	  the	  assay.	  	  
	   Our	  data	  suggests	  that	  an	  IL-­‐‑2	  gradient	  is	  capable	  of	  inducing	  the	  migration	  of	  
primary	  VSMCs	  isolated	  from	  the	  human	  aorta.	  	  









Figure	  10.	  IL-­‐‑2	  treatment	  causes	  migration	  of	  VSMCs.	  	  
Boyden	  chamber	  assay	  was	  done	   in	  a	  24	  well	  plate	   to	  asses	  VSMC	  migration.	  
Inner	   chamber	   was	   loaded	   with	   2x105	   cells	   in	   DMEM	   while	   outer	   chamber	  
received	  DMEM	  alone.	  Plate	  was	   incubated	   for	  24hrs	  at	  37ºC.	   Inner	   chamber	  
media	  was	  replaced	  with	  DMEM	  while	  outer	  chamber	  was	  replaced	  with	  DMEM	  
containing	  30ng/mL	  of	  IL-­‐‑2	  or	  PDGF.	  After	  8	  hr.	  incubation	  at	  37°C,	  chambers	  
were	  washed	   in	   PBS	   and	   fixed	   in	  methanol.	   Cells	  were	   visualized	   using	   sybr	  
green	  (life	  technologies)	  and	  imaging	  using	  FITC	  channel	  on	  an	  EVOS	  FL	  imaging	  
system.	  (*	  p	  <	  0.05)	  n	  =	  4	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Summary	  and	  Discussion	  
	   We	  have	  presented	  a	  novel	  finding	  that	  IL-­‐‑2	  causes	  migration	  of	  VSMCs.	  The	  
Boyden	  chamber	  was	  used	  to	  test	  the	  capacity	  for	  IL-­‐‑2	  to	  enable	  VSMCs	  to	  become	  
mobile.	  PDGF,	  a	  potent	  motogen	  of	  VSMCs	  was	  used	  as	  a	  positive	  control	   to	  verify	  
proper	  execution	  of	  the	  Boyden	  chamber	  assay.	  
	   To	  solidify	  our	  findings,	  components	  responsible	  for	  VSMC	  migration	  can	  be	  
examined	   for	   participation	   in	   IL-­‐‑2	   mediated	   migration	   of	   VSMCs	   including	   FAK,	  
vinculin,	   paxillin,	   tensin,	   p130cas,	   and	  Src.	   Signaling	   results,	   discussed	   later,	   show	  
prominent	  activation	  of	  ERK(1/2)	  in	  response	  to	  IL-­‐‑2,	  thus	  providing	  a	  mechanism	  
by	  which	  VSMCs	  may	  assemble	  the	  machinery	  that	  is	  responsible	  mobilizing	  the	  cells.	  	  
	   This	   finding	   has	   implications	   in	   VSMC	   mediated	   pathologies.	   A	   critical	  
component	  of	  the	  progression	  of	  atherosclerosis	  is	  VSMC	  migration	  from	  the	  tunica	  
media	  into	  the	  tunica	  intima	  where	  VSMCs	  contact	  and	  process	  locally	  accumulated	  
LDL	  and	  transform	  into	  foam	  cells.	  Not	  only	  is	  IL-­‐‑2	  present	  within	  the	  vasculature,	  IL-­‐‑
2	  has	  been	  shown	  to	  be	  elevated	  in	  atherosclerosis,	  most	  likely	  secreted	  by	  infiltrating	  
T-­‐‑cells.	  IL-­‐‑2,	  thus,	  as	  part	  of	  the	  inflammatory	  process,	  may	  facilitate	  the	  recruitment	  











IL-­‐‑2	  Receptor	  Expression	  In	  VSMCs	  
Vascular	  Smooth	  Muscle	  Cells	  Express	  the	  Complete	  IL-­‐‑2	  Receptor	  
The	  IL-­‐‑2	  Receptor	  
IL-­‐‑2	   binds	   to	   its	   receptor	   which	   is	   comprised	   of	   three	   components:	   α	   (IL-­‐‑
2Rα/CD25),	   β	   (IL-­‐‑2Rβ/CD122)	   and	   γ	   (IL-­‐‑2Rγ/CD132).	   IL-­‐‑2	   binds	   in	   a	   sequential	  
manner	   to	   the	  components	  of	   the	   IL-­‐‑2	  receptor.	  First,	   IL-­‐‑2Rα,	   second,	   IL-­‐‑2Rβ,	   and	  
third,	   IL-­‐‑2Rγ	   (Pillet	   et	   al.	   2010).	   The	   heterodimerization	   of	   IL-­‐‑2Rβ	   and	   IL-­‐‑2Rγ	   is	  
responsible	   for	   signaling	   transduction	   through	   their	   tyrosine-­‐‑kinase	   cytoplasmic	  
region.	  The	  resulting	  signal	  is	  carried	  via	  three	  main	  signaling	  pathways:	  Janus	  Kinase	  
(JAK),	  phosphoinositide	  3-­‐‑kinase	  (PI3K)-­‐‑AKT,	  and	  mitogen-­‐‑activated	  protein	  kinase	  
(MAPK).	  These	  pathways	  have	  been	  generally	  known	  to	  promote	  survival,	  activation	  
and	  proliferation	  of	  the	  target	  cell	  (Imada	  and	  Leonard	  2000;	  W.	  Kuziel	  and	  Greene	  
1990).	  
IL-­‐‑2Rβ	   and	   IL2-­‐‑Rγ	   receptor	   components	   have	   dual	   functions.	   IL-­‐‑2Rβ,	   in	  
addition	   to	   binding	   IL-­‐‑2,	   serves	   as	   the	   β	   component	   for	   IL-­‐‑15R.	   Similarly,	   IL-­‐‑2Rγ	  
serves	  as	  an	  integral	  portion	  of	  IL-­‐‑4,	  IL-­‐‑7,	  IL-­‐‑9,	  IL-­‐‑15,	  and	  IL-­‐‑21	  receptors	  and	  suitably,	  
it	  also	  is	  known	  as	  the	  common	  γ	  chain	  (Liao	  et	  al.	  2013).	  	  
	   The	  importance	  of	  the	  IL-­‐‑2	  receptor	  becomes	  clear	  when	  considering	  that	  the	  
IL-­‐‑2Rγ	   is	   essential	   for	   survival.	   The	   absence	   or	   defect	   of	   IL-­‐‑2Rγ	   leads	   to	   Severe	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Combined	  Immunodeficiency	  Disorder	  (SCID)	  in	  humans,	  which	  is	  a	  crippling	  illness	  
that	   leaves	   the	   affected	   individual	   without	   a	   functional	   adaptive	   immune	   system	  
(Leonard	  2001).	  Furthermore,	  studies	  show	  that	  IL-­‐‑2Rα	  and	  IL-­‐‑2Rβ	  knockout	  mice	  
develop	  terminal	  autoimmune	  conditions	  such	  as	  hemolytic	  anemia	  and	  ulcerative	  
colitis.	  Cells	  most	  affected	  by	  such	  a	  knock	  out	  are	  NK	  cells	  and	  T-­‐‑regulatory	  cells	  
(Felices	   et	   al.	   2014;	   Malek	   2003).	   	   Impaired	   T-­‐‑regulatory	   cell	   development	   and	  
function	   is	   believed	   to	   be	   the	   cause	   of	   the	   progression	   of	   these	   fatal	   autoimmune	  
conditions	  (Roncarolo	  and	  Levings	  2000).	  	  
Expression	  of	  each	  subunit	  of	  the	  IL-­‐‑2	  receptor	  is	  regulated	  by	  an	  unknown	  
mechanism	  that	  relies	  on	  the	  type	  and	  the	  maturation	  stage	  of	  a	  particular	  cell.	   In	  
developing	  CD4+	  T-­‐‑cells,	  IL-­‐‑2Rα	  is	  expressed	  prominently,	  while	  IL-­‐‑2Rβ	  expression	  is	  
barely	  detectable.	  In	  mature,	  naïve	  CD4+	  T-­‐‑cells,	  the	  IL-­‐‑2Rβ	  surges	  in	  expression	  while	  
expression	  of	  the	  IL-­‐‑2Rα	  becomes	  significantly	  diminished	  and	  sequestered	  within	  
vesicles	  (Kondo	  et	  al.	  1994).	  The	  IL-­‐‑2Rα	  only	  surges	  in	  expression	  and	  engages	  the	  β-­‐‑
γ	   complex	   after	   immune	   activation	   of	   the	   cell	   by	   its	   T-­‐‑cell	   receptor	   and	   CD40L	  
(Ballard	   2001).	   B	   cells	   differ	   significantly	   from	   T-­‐‑cells	   by	   expressing	   all	   three	  
components	  of	  the	  IL-­‐‑2	  receptor	  in	  early	  stages,	  but	  mature	  B-­‐‑cells	  express	  only	  the	  
γ	   subunit	   (Steinberger	   et	   al.	   1997).	   IL-­‐‑2	   receptor	   expression	   has	   been	   studied	  
primarily	   in	   lymphoid	   cells	   in	   the	   past.	   However,	   recent	   studies	   suggest	   that	   IL-­‐‑2	  
receptors	  are	  on	  an	  increasing	  number	  of	  non-­‐‑lymphoid	  cells	  such	  as	  endothelial	  cells	  
and	  fibroblasts	  (Arenas-­‐‑ramirez	  et	  al.	  2015;	  Gruss	  et	  al.	  1996).	  	  Considering	  that	  the	  
IL-­‐‑2	  receptor	  has	  been	  found	  on	  cells	  outside	  the	  lymphoid	  lineage,	  it	  is	  very	  likely	  
that	  it	  is	  more	  prevalent	  than	  presently	  understood.	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The	   idea	  of	   cytokine	   receptor	  expression	  by	  VSMCs	   is	  not	   as	  novel	   as	  once	  
thought	  given	  reports	  of	  functional	  IL-­‐‑4	  and	  IL-­‐‑15	  receptors	  by	  VSMCs	  (Hocke	  et	  al.	  
2007;	  Hofbauer	  et	  al.	  2006).	  Interestingly,	  the	  IL-­‐‑15	  receptor	  β	  and	  IL-­‐‑4	  receptor	  γ	  
components	  also	  serve	  as	  β	  and	  γ	  components	  of	  the	  IL-­‐‑2	  receptor	  respectively	  (W.	  A.	  
Kuziel	  and	  Greene	  1990).	  The	  IL-­‐‑2Rα	  component	  has	  never	  before	  been	  shown	  to	  be	  
present	  in	  VSMCs,	  but	  it	  is	  very	  likely	  to	  be	  present	  since	  only	  the	  heterotrimeric	  IL-­‐‑2	  
receptor	  comprised	  of	  the	  α,	  β	  and	  γ	  components	  are	  functional	  in	  lymphocytes	  (W.	  
Kuziel	  and	  Greene	  1990).	  	  
IL-­‐‑2	   receptor	  mRNA	   is	   present	   in	   VSMCs	   (Figures	   11	   and	   12).	   rtPCR	   of	  mRNA	  
isolated	  from	  VSMCs	  using	  intron-­‐‑spanning	  primers	  specific	  to	  each	  component	  of	  the	  
IL-­‐‑2	  receptor	  resulted	  in	  singular	  bands	  of	  expected	  sizes.	  These	  PCR	  products	  were	  
purified	  and	  sequenced	  by	  Sanger	  sequencing	  (Eurofins	  Genomics,	  Louisville,	  KY)	  and	  
the	  resulting	  sequences	  matched	  published	  sequences	  of	  IL-­‐‑2	  receptor	  components	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Figure	  11.	  Each	  IL-­‐‑2	  Receptor	  component	  mRNA	  was	  detected	  
by	   RT-­‐‑PCR	   using	   intron	   spanning	   primers.	   Complete	   cDNA	  
sequences	   of	   IL-­‐‑2	   receptor	   components	   were	   obtained	   from	  
GenBank.	   Intron	   spanning	   primers	   were	   designed	   using	   the	  
PrimerQuest	   tool	   from	   Integrated	   DNA	   Technologies.	   Cultured	  
VSMC	  RNA	  was	  purified	  from	  multiple	  donors	  (n>3)	  using	  Trizol	  
(Life	  Technologies,	  Carlsbad,	  CA)	  and	  treated	  with	  Turbo	  DNAse	  
Free	   (ThermoFisher	   Scientific,	   Carlsbad,	   CA).	   rtPCR	   was	  
performed	  using	   the	  aforementioned	  primers	  and	   the	  amplified	  
products	  were	  separated	  electrophoretically	  in	  a	  1.5%	  agarose	  gel	  
containing	   0.5ug/mL	   ethidium	   bromide.	   PCR	   products	   were	  
visualized	   using	   UV	   light	   and	   the	   image	   was	   captured	   using	  
ChemiDoc	  MP	  imaging	  system	  (BioRad).	  






Figure	  12.	  The	  IL-­‐‑2R	  α	  RT-­‐‑PCR	  product	  from	  VSMCs	  match	  known	  sequences	  of	  IL-­‐‑2R	  cDNA	  
reported	   in	   lymphocytes.	  Amplified	   IL-­‐‑2	   receptor	  α	   segments	   from	  cultured	  VSMC	  cDNA	  were	  
purified	  using	  QIAquick	  PCR	  purification	  kit	  and	  submitted	  for	  sequencing	  (Eurofins	  Genomics).	  The	  
resulting	  sequences	  were	  compared	  with	  currently	  known	  human	  transcripts	  using	  the	  standard	  
nucleotide	  BLAST	  from	  NCBI.	  A.	  Results	  show	  a	  100%	  match	  to	  human	  IL-­‐‑2	  receptor	  IL-­‐‑2	  receptor	  α	  
(GI:	  NM_000417),	  97-­‐‑100%	  match	  to	  human	  IL-­‐‑2	  receptor	  β	  (GI:	  NM_000878)	  97-­‐‑100%	  match	  to	  γ	  	  
(GI:	  NM_000206).	  n=3	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The	  IL-­‐‑2	  receptor	  protein	  is	  expressed	  in	  VSMCs	  (Figure	  13).	  To	  establish	  the	  
presence	  of	  the	  IL-­‐‑2	  receptor	  protein	  in	  VSMCs,	  lysates	  from	  cultured	  human	  VSMCs	  
were	  subject	  to	  western	  blot	  analysis	  using	  antibodies	  against	  IL-­‐‑2	  receptors	  α,	  β,	  
and	  γ.	  Lysates	  from	  E6-­‐‑1	  cells	  were	  used	  as	  positive	  controls	  for	  expression	  of	  all	  IL-­‐‑
2	  receptor	  components	  (Abraham	  and	  Weiss	  2004).	  	  
The	   resulting	   images	   show	   that	  VSMC	   lysate	   lanes	   contain	  banding	  pattern	  
that	   match	   those	   from	   the	   lymphocyte	   lysate	   lanes,	   indicating	   the	   presence	   of	   a	  
complete	  IL-­‐‑2	  receptor	  within	  cultured	  VSMCs	  (n=3).	  Our	  data	  therefore	  suggests	  that	  
the	  IL-­‐‑2	  receptor	  protein	  is	  expressed	  in	  human	  aortic	  VSMCs.	  	  
IL-­‐‑2	  receptor	  α	  immunofluorescence	  (Figure	  14).	  IL-­‐‑2	  receptor	  VSMCs	  were	  
stained	   using	   an	   IL-­‐‑2	   two	   separate	   receptor	  α	   antibodies	   and	   visualized	   using	   as	  
described	   in	   the	  Methodology	   section.	  Upon	   imaging,	  we	  observed	  a	   strong	   signal	  
forming	   what	   appears	   to	   the	   nuclear	   envelope	   from	   both	   antibodies.	   Secondary	  
controls	  were	  negative	  and	  blocking	  peptide	  addition	  reduced	  the	  fluorescent	  signals	  
from	  IL-­‐‑2	  receptor	  α	  significantly.	  Our	  control	  staining	  images	  suggest	  proper	  protein	  
binding	  specificity	  of	  the	  IL-­‐‑2	  receptor	  α	  antibody.	  	  	  
IL-­‐‑2	  receptor	  α	   	   protein	  expression	   is	  decreased	   in	   the	  presence	  of	   fetal	  
bovine	  serum	  (Figure	  15).	  In	  order	  to	  understand	  the	  functions	  of	  the	  IL-­‐‑2	  receptor,	  
we	  sought	  to	  determine	  if	  IL-­‐‑2	  receptor	  expression	  fluctuates	  between	  VSMCs	  that	  
are	  quiescent	  and	  VSMCS	  that	  are	  proliferating.	  Thus,	  VSMCs	  cultured	  in	  flasks	  for	  72	  
hr	   in	   the	   presence	   or	   absence	   of	   FBS	   were	   assessed	   for	   IL-­‐‑2	   receptor	   α	   protein	  
expression	   using	   western	   blot	   analysis.	   IL-­‐‑2	   receptor	   α	   band	   was	   significantly	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reduced	  in	   intensity	   in	  the	  protein	  sample	  from	  VSMCs	  treated	  with	  FBS.	  Our	  data	  
suggests	  that	  FBS	  treatment	  reduces	  IL-­‐‑2	  receptor	  	  α	  expression.	  	  
	   Each	  IL-­‐‑2	  receptor	  component	  displays	  a	  unique	  pattern	  of	  localization	  in	  
VSMCs	  (Figure	  16).	  Primary	  VSMCs	  were	  lysed	  and	  fragmented	  into	  three	  fractions:	  
cytoplasmic,	   membrane/organelle,	   and	   nuclear.	   Equal	   protein	   amounts	   were	  
assessed	  for	  IL-­‐‑2	  receptor	  component	  expression	  using	  western	  blot	  analysis.	  Control	  
proteins	   were	   visualized	   in	   each	   sample	   to	   assess	   quality	   of	   cellular	   component	  
separation.	  MEK	  protein	  was	   expected	   in	   the	   cytoplasmic	   fraction,	   AIF	   (apoptosis	  
induction	  factor)	  was	  expected	  to	  be	  in	  the	  cell	  membrane	  fraction,	  and	  Histones	  were	  
expected	  to	  be	  in	  the	  nuclear	  fraction.	  	  
Our	  data	  suggests	  that	  IL-­‐‑2	  receptor	  α	   localizes	  both	  to	  the	  nucleus	  and	  the	  
cytoplasm	  while	  the	  IL-­‐‑2	  receptor	  β	  is	  present	  primarily	  in	  the	  nucleus	  VSMCs.	  IL-­‐‑2	  
receptor	  γ	  expression	  localized	  to	  the	  nucleus	  and	  the	  cell	  membrane.	  








IL-­‐‑2	  Receptor	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IL-­‐‑2	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Figure	  13.	  IL-­‐‑2	  protein	  subunits	  of	  the	  IL-­‐‑2	  receptor	  are	  expressed	  on	  VSMCs.	  	  
Total	   lysates	   from	  lymphocytes	  (E6-­‐‑1	  cell	   line)	  and	  VSMCs	  were	   fractionated	  by	  SDS-­‐‑PAGE	  using	  a	  
10%	   polyacrylamide	   gel.	   Proteins	   were	   transferred	   onto	   a	   PVDF	   membrane	   and	   probed	   with	  
antibodies	  against	  IL-­‐‑2	  receptor	  α,	  β	  or	  γ	  followed	  by	  a	  secondary	  antibody	  conjugated	  to	  HRP.	  The	  
membrane	  was	  later	  visualized	  using	  an	  ECL	  substrate	  and	  ChemiDoc	  MP	  imaging	  system	  (Biorad).	  
Lymphocytes	   VSMCs	  
Lymphocytes	   VSMCs	  
Lymphocytes	   VSMCs	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Figure	  14.	  	  IL-­‐‑2	  receptor	  α	  immunofluorescence.	  	  
IL-­‐‑2	   receptor	   VSMCs	   were	   plated	   in	   a	   8	   well	   chamber	   slide	   plate	   and	   allowed	   to	   reach	   75%	  
confluence	  in	  an	  incubator	  at	  37°C,	  and	  5%	  CO2.	  Fixation	  of	  these	  cells	  was	  carried	  out	  with	  a	  mixture	  
of	  methanol:acetic	  acid	  (20:1)	  at	  -­‐‑80°C	  for	  10	  minutes,	  then	  rinsed	  three	  times	  with	  PBS	  and	  blocked	  
for	  1hr.	  in	  PBS	  containing	  5%	  BSA.	  (A)The	  cells	  were	  later	  incubated	  with	  the	  IL-­‐‑2	  receptor	  antibody	  
(Boster	  Bio,	  Pleasanton,	  CA)	  at	  5ug/mL	  in	  PBS	  containing	  5%	  BSA	  buffer	  and	  incubated	  overnight	  at	  
room	  4°C.	   Cells	  were	   then	  washed	  with	   PBST,	   and	  probed	   for	  1.5	  hrs.	  using	   secondary	   antibody	  
conjugated	  to	  Alexa	  Fluor	  (Life	  Technologies,	  Carlsbad,	  CA)	  at	  1:2000	  dilution.	  (B)	  Fixed	  cells	  were	  
incubated	  with	  A	  blocking	  peptide	  prior	  to	  following	  staining	  procedure	  to	  confirm	  the	  specificity	  of	  
the	  primary	  antibody.	  Blocking	  peptide	  was	  used	   according	   to	  manufacturer	   instructions	   (1:100	  
dilution	   in	   PBS/BSA	   5%	  buffer).	   (C)	   Primary	   antibody	  was	   omitted	  while	   following	   our	   staining	  
procedure.	  (A-­‐‑C)	  EVOS	  FL(Life	  Technologies,	  Carlsbad,	  CA)	  was	  used	  to	  capture	  images.	  All	  images	  
were	  taken	  at	  the	  same	  time	  at	  20x	  magnification	  and	  exposure.	  (D)	  90	  sectional	  images	  were	  taken	  
with	  Olympus	  fv3000	  confocal	  scanning	  electron	  microscope.	  Images	  were	  by	  z-­‐‑stack	  using	  Image	  J	  
software	  (NIH).	  	  
A.	  IL-­‐‑2	  receptor	  α	   B.	  IL-­‐‑2	  receptor	  α	  +	  Blocking	  Peptide	  
C.	  Isotype	   D.	  IL-­‐‑2	  receptor	  α	  	  	  Merged	  Confocal	  
Image	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Figure	  15.	  IL-­‐‑2	  receptor	  α	  expression	  is	  altered	  by	  fetal	  bovine	  serum.	  VSMCs	  were	  cultured	  in	  75	  
cm2	  flasks	  to	  confluence	  using	  complete	  DMEM	  media	  for	  72	  hrs	  followed	  by	  48	  hrs	  of	  serum	  starvation.	  
Designated	  flasks	  were	  treated	  with	  10%	  FBS,	  or	  100ng/mL,	  or	  DMEM	  allowed	  to	  incubate	  at	  37°	  C.	  After	  
48hrs,	  total	  lysates	  from	  VSMCs	  were	  collected	  and	  the	  protein	  amounts	  were	  quantified	  by	  BCA.	  Equal	  
amounts	  of	  protein	  from	  each	  sample	  were	  fractionated	  by	  SDS	  page	  using	  a	  10%	  polyacrylamide	  gel.	  
Proteins	  were	  transferred	  onto	  a	  PVDF	  membrane	  and	  probed	  with	  antibodies	  against	  IL-­‐‑2	  receptor	  α	  
followed	  by	  a	  secondary	  antibody	  conjugated	  to	  HRP.	  The	  membrane	  was	  later	  visualized	  using	  an	  ECL	  
substrate	  and	  ChemiDoc	  MP	  imaging	  system	  (Bio-­‐‑Rad,	  Hercules,	  CA).	  n	  =	  3	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Figure	  16.	  IL-­‐‑2	  receptor	  components	  localize	  to	  the	  nucleus	  of	  VSMCs.	  
	  Primary	  VSMCs	  were	  lysed	  and	  fragmented	  into	  three	  fractions:	  cytoplasmic,	  membrane/organelle,	  and	  
nuclear/cytoskeletal.	   An	   equal	   amount	   of	   each	   fraction	   was	   separated	   by	   SDS-­‐‑PAGE	   in	   a	   4-­‐‑12%	  
polyacrylamide	  gradient	  gel	  and	  transferred	  onto	  a	  PVDF	  membrane.	  The	  membrane	  was	  probed	  with	  
antibodies	  against	   IL-­‐‑2	  receptor	  α,	  β,	  γ	  or	  cell	   fractionation	  control	  antibodies	   followed	  by	  a	  secondary	  
antibody	  conjugated	  to	  HRP.	  The	  membrane	  was	  later	  visualized	  using	  an	  ECL	  substrate	  and	  ChemiDoc	  
MP	  imaging	  system	  (Biorad,	  Hercules,	  CA).	  n=	  3	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Summary	  and	  Discussion	  
VSMCs	   have	   been	   previously	   shown	   to	   express	   the	   IL-­‐‑2	   receptor	   β	   and	   γ	  
components.	  We	  asked	  whether	  VSMCs	  also	  express	  the	  IL-­‐‑2	  receptor	  α	  component	  
to	   form	   the	   complete	   heterotrimeric	   IL-­‐‑2	   receptor	   and	   identify	   their	   cellular	  
localization	  within	  VSMCs.	  	  
The	  combined	  results	  from	  rtPCR,	  western	  blot	  and	  immunostaining	  provide	  
strong	  evidence	  that	  the	  IL-­‐‑2	  receptor	  α	  is	  expressed	  in	  VSMCs.	  Immunostaining	  and	  
western	   blot	   analysis	   of	   VSMC	   cell	   fractionations	   illustrate	   that	   IL-­‐‑2	   receptor	  α	   is	  
present	   on	   the	   nuclear	   membrane.	   We	   also	   found	   unique	   expression	   patterns	  
between	  the	  IL-­‐‑2	  receptor	  components	  within	  VSMCs.	  IL-­‐‑2	  receptor	  α	  localizes	  both	  
to	  the	  nucleus	  and	  the	  cytoplasm	  while	  the	  IL-­‐‑2	  receptor	  β	  is	  present	  primarily	  in	  the	  
nucleus	  VSMCs	  and	  minimally	  to	  the	  cytoplasm.	  IL-­‐‑2	  receptor	  γ	  expression	  localized	  
to	  the	  nucleus	  and	  the	  cell	  membrane.	  
Our	  discovery	  of	  the	  presence	  of	  IL-­‐‑2	  α	  receptor	  in	  VSMCs	  and	  the	  predilection	  
of	  all	   IL-­‐‑2	  receptor	  subunits	   to	   localize	   to	   the	  nuclear	  envelope	  are	  novel	   findings.	  
Based	   on	   their	   individual	   compartmentalization	  within	   cells,	   it	  maybe	   possible	   to	  
conjecture	   that	   IL-­‐‑2R	   γ	   found	   in	   the	   cell	  membrane	  makes	   first	   contact	   simply	  by	  
being	  the	  only	  IL-­‐‑2	  receptor	  component	  exposed	  to	  the	  extracellular	  matrix.	  These	  
receptors	  are	  known	  to	  form	  homodimers	  that	  bind	  IL-­‐‑2.	  They	  may	  be	  endocytosed	  
and	   translocated	   by	   proteins	   such	   as	   Sec61.	   Sec61	   translocates	   to	   the	   nuclear	  
envelope	  to	  initiate	  a	  signaling	  cascade	  	  as	  recently	  described	  using	  EGF	  (Denks	  et	  al.	  
2014;	  Lerner-­‐‑Marmarosh	  et	  al.	  2008).	  	  
	   55	  
To	  determine	  if	  IL-­‐‑2Rα	  expression	  is	  under	  transcriptional	  regulation	  VSMCs	  
as	   found	   in	   lymphocytes,	   we	   compared	   IL-­‐‑2Rα	   expression	   between	   treated	   and	  
untreated	   cells.	   We	   found	   that	   IL-­‐‑2Rα	   expression	   decreased	   significantly	   in	   the	  
presence	  of	  fetal	  bovine	  serum	  and	  was	  slightly	  elevated	  after	  the	  addition	  of	  IL-­‐‑2.	  
This	   pattern	   of	   regulation	   of	   the	   IL-­‐‑2	   receptor	  α	   has	   been	   previously	   reported	   in	  
lymphocytes	   (W.	   A.	   Kuziel	   and	   Greene	   1990).	   Thus	   similar	   mechanisms	   maybe	  
responsible	  for	  regulation	  of	  IL-­‐‑2Rα	  in	  VSMCs	  as	  in	  lymphocytes.	  	  
	  





IL-­‐‑2	  Mediated	  Signaling	  in	  Vascular	  Smooth	  Muscle	  Cells	  
IL-­‐‑2	  Signaling	  
The	   extracellular	   IL-­‐‑2	   signal	   is	   transmitted	   to	   the	   cytoplasm	   through	   the	  
intracellular	  regions	  of	  the	  IL-­‐‑2	  receptor	  β	  and	  γ	  subunits.	  The	  intracellular	  region	  of	  
the	  IL-­‐‑2R	  β	  contains	  3	  main	  domains:	  serine	  rich,	  acidic	  and	  c-­‐‑terminal	  (Gesbert	  et	  al,	  
1998).	  Cell	  proliferation	   is	   initiated	   from	  signals	  originating	   from	  either	   the	  acidic	  
domain	  or	  c-­‐‑terminal	  domain,	  in	  combination	  with	  signals	  originating	  from	  the	  serine	  
rich	   domain.	   The	   serine	   rich	   domain	   gives	   rise	   to	   signals	   that	   control	   the	   up-­‐‑
regulation	   of	   anti-­‐‑apoptotic	   protein	   bcl-­‐‑2	   and	   pro-­‐‑proliferative	   protein	   c-­‐‑myc	  
(Lindemann,	  Benczik,	  and	  Gaffen	  2003;	  Miyazaki	  et	  al.	  1995).	  The	  signals	  originating	  
from	  the	  acidic	  domain	  lead	  to	  up-­‐‑regulation	  of	  the	  cell	  cycle	  regulators	  c-­‐‑fos	  and	  c-­‐‑
jun.	  The	  C-­‐‑terminal	  domain	  is	  responsible	  for	  activation	  of	  the	  transcription	  factor	  
STAT5	  (Gesbert	  et.	  al,	  1998).	  	  
	   Since	  the	  IL-­‐‑2	  receptor	  has	  no	  intrinsic	  phosphotyrosine	  activity,	  it	  relies	  on	  
cytoplasmic	  proteins	   to	  phosphorylate	   tyrosine	   residues	   found	   in	   the	   intracellular	  
region.	  These	  kinases	  are	  better	  known	  as	  non-­‐‑receptor	  associated	  phosphotyrosine	  
kinases.	  The	  protein	  kinases	  that	  phosphorylate	  the	  IL-­‐‑2	  receptor	  tyrosine	  residues	  
are	  Janus	  Kinase	  1	  (JAK1)	  and	  Janus	  Kinase	  3(JAK3).	  The	  intracellular	  N-­‐‑terminus	  of	  
the	  β	  subunit	  is	  associated	  with	  JAK1	  while	  JAK3	  is	  associated	  with	  the	  N-­‐‑terminus	  of	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the	   γ	   subunit	   (Kawahara	   et	   al.	   1995).	   Upon	   binding	   IL-­‐‑2,	   the	   β	   and	   γ	   subunits	  
dimerize,	   leading	   to	   the	   apposition	   of	   JAK1	   and	   JAK3	   and	   their	   subsequent	  
transactivation	  (Babon	  et	  al.	  2014).	  
The	   activated	   form	   of	   JAK	   1	   and	   JAK3	   are	   responsible	   for	   phosphorylating	  
three	  tyrosine	  residues	  of	  the	  cytoplasmic	  domains	  of	  the	  IL-­‐‑2	  receptor	  β:	  Y338,	  Y392	  
and	  Y510.	  These	  phosphorylated	  regions	  of	  the	  IL-­‐‑2	  receptor	  become	  docking	  sites	  
for	  specific	  proteins	  containing	  an	  N-­‐‑terminal	  src-­‐‑homology	  2	  (SH2)	  domain	  such	  as	  
the	  adaptor	  protein	  Shc	  (binds	  Y338)	  and	  STAT5	  (binds	  Y392	  and	  Y510)	  (Babon	  et	  al.	  
2014;	   Liu	   et	   al.	   1997).	   The	   binding	   of	   these	   two	   proteins	   mark	   the	   splitting	   of	  
signaling	  transmission	   into	  a	  3	  major	  pathways:	  Phosphoinositide-­‐‑3-­‐‑Kinase	  (PI3K)	  
pathway,	  Mitogen	  Activated	  Protein	  Kinase	  (MAPK)	  pathway	  and	  the	  STAT5	  pathway	  
(Malek	  and	  Castro	  2010).	  	  
The	  adaptor	  protein	  Shc	  binds	  the	  IL-­‐‑2R	  β	  phosphotyrosine	  residue	  338,	  and	  
allows	  for	  the	  formation	  of	  an	  oligomeric	  scaffold	  by	  combining	  with	  growth	  factor	  
receptor-­‐‑bound	  protein	  2	  (Grb2)	  and	  son	  of	  sevenless	  (SOS).	   	  The	  SOS	  protein	  is	  a	  
GTP	  exchange	  factor	  that	  activates	  the	  small	  GTPase	  protein	  called	  Ras	  (Ravichandran	  
and	  Burakoff	  1994).	  Ras	  initiates	  the	  MAP	  kinase	  pathway	  that	  ultimately	  leads	  to	  the	  
activation	  of	  three	  main	  proteins	  that	  translocate	  to	  the	  nucleus	  to	  serve	  as	  regulators	  
of	  gene	  expression:	  Extracellular	  signal-­‐‑regulated	  kinase	  ERK	  1/2,	  c-­‐‑Jun	  N-­‐‑terminal	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Mitogen	  Activated	  Kinase	  (MAPK)	  Pathway	  
	  	   The	  MAPK	   pathway	   consists	   of	   a	   highly	   conserved	   chain	   reaction	   of	   three	  
Ser/Thr-­‐‑specific	  kinases:	  MKKK,	  MKK	  (MEK),	  and	  MAPK.	  MAPK	  components	  interact	  
with	   many	   regulatory	   proteins	   such	   as	   protein	   phosphatases,	   scaffold	   proteins,	  
nuclear	  proteins	  and	  regulatory	  regions	  of	  DNA	  (Krishna	  and	  Narang	  2008).	  
	   There	  are	  four	  main	  MAPK	  proteins	  (Figure	  17),	  each	  of	  which	  lead	  to	  a	  unique	  
cellular	  response:	  JNK,	  p38,	  ERK,	  and	  Big	  MAP	  Kinase-­‐‑1	  (BMK1	  or	  ERK5).	  The	  ERK	  
pathway	  typically	  responds	  to	  growth	  factor	  signals	  while	  the	  JNK	  and	  p38	  pathways	  
respond	  to	  a	  variety	  of	  extracellular	  stress	  signals.	  Compounding	  the	  complexity	  of	  
this	  signaling	  pathway,	  each	  MAPK	  component	  is	  encoded	  by	  multiple	  genes	  (ERK1	  
and	  ERK,	  JNK1,	  JNK2,	  JNK3,p38a,	  p38b,	  p38g,	  p38d)	  and	  isoforms	  are	  generated	  by	  
differential	  splicing	  (Krishna	  and	  Narang	  2008).	  	  
	   MAPKs	   translocate	   to	   the	   nucleus	   to	   regulate	   transcription	   by	   binding	  
regulatory	  regions	  of	  DNA	  or	  by	  forming	  a	  complex	  with	  other	  transcription	  factors	  
(Whitmarsh	  2007).	  Without	  a	  stimulus,	  ERKs,	  are	  located	  in	  the	  cytoplasm	  bound	  to	  
regulatory	   proteins.	   Within	   minutes	   of	   activation,	   ERKs	   dissociate	   from	   the	  
regulatory	   protein	   and	   translocate	   into	   the	   nucleus.	   The	   mechanism	   of	   this	  
translocation	  is	  not	  entirely	  understood	  but	  there	  have	  been	  a	  few	  reports	  proposing	  
a	  number	  of	  possibilities:	  
	  
1.   ERK	  can	  directly	  translocate	  to	  the	  nucleus	  after	  it	  is	  phosphorylated	  by	  casein	  
kinase	  2.	  Once	  in	  the	  nucleus,	  ERK	  binds	  to	  the	  nuclear	  transport	  protein	  Imp7	  
(Yang,	  Sharrocks,	  and	  Whitmarsh	  2003).	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2.   Some	  nuclear	   import	  of	  ERK	  and	   JNK	  can	  be	   facilitated	  by	   their	  association	  
with	  proteins	  that	  contain	  the	  NLS	  (define	  NLS).	  For	  example,	  ERK	  has	  been	  
shown	  to	  bind	  biliverdin	  reductase	  (Lerner-­‐‑Marmarosh	  et	  al.	  2008)	  and	  JNK	  
has	  been	  reported	  to	  enter	  the	  nucleus	  by	  its	  association	  with	  c-­‐‑Jun	  (Schreck	  
et	  al.	  2011).	  	  
3.   ERK	  also	  is	  shuttled	  into	  the	  nucleus	  through	  binding	  with	  Mxi2,	  a	  nucleopore	  
binding	  splice	  variant	  of	  p38a.	  	  Mxi2	  has	  been	  shown	  to	  protect	  deactivation	  
of	  ERK,	  enhancing	  nuclear	  functions	  of	  ERK	  (Casar	  et	  al.	  2011).	  	  
4.   ERK1	  and	  ERK2	  can	  form	  homodimers	  which	  have	  been	  reported	  to	  enter	  the	  
nucleus	  more	   rapidly	   than	   their	  monomeric	   counterparts	   (Adachi,	   Fukuda,	  
and	  Nishida	  1999).	  However,	  the	  theory	  of	  the	  efficient	  nuclear	  translocation	  
of	  dimeric	  ERK	  is	  controversial.	  
	  
	  Investigations	  into	  the	  mechanism	  of	  MAPK’s	  transit	  into	  the	  nucleus	  are	  limited	  and	  
don’t	  support	  a	  unifying	  theory,	  thus	  a	  great	  deal	  of	  research	  is	  necessary	  on	  this	  topic	  
to	  promote	  a	  better	  understanding,	  particularly	  on	  the	  nuclear	  translocation	  of	  JNK	  
and	  p38	  proteins.	  	  
Following	   entry	   into	   the	   nucleus,	   MAPKs	   phosphorylate	   and	   regulate	   the	  
functions	   of	  many	   proteins	   involved	   in	   transcriptional	   regulation.	   	  MAPKs	  modify	  
gene	  expression	  by	  histone	  acetylation,	  phosphorylation	  of	  transcription	  factors	  (eg.	  
members	  of	  the	  ternary	  complex	  factor)	  or	  activation	  of	  other	  kinases	  (eg.	  MSK	  1/2).	  
In	  addition,	  ERK	  has	  even	  been	  shown	  to	  modulate	  gene	  expression	  by	  docking	  onto	  
transcription	  factors	  already	  bound	  to	  a	  DNA	  response	  element	  (Whitmarsh	  2007).	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Ternary	  Complex	  Factor-­‐‑Serum	  Response	  Factor	  system	  and	  MAPKs	  
The	  ternary	  complex	   factors	  (TCFs)	  are	  a	  subfamily	  of	   transcription	   factors	  
that	  are	  activated	  through	  phosphorylation	  by	  MAPKs.	  There	  are	  three	  main	  TCFs:	  
Elk-­‐‑1,	  SAP-­‐‑1	  and	  SAP-­‐‑2.	  Ternary	  complex	  factors	  contain	  four	  domains:	  DNA	  binding,	  
B,	  C	  and	  D	  domains.	  The	  D-­‐‑domain	   is	   a	  docking	   site	   for	  MAPKs	  and	   the	  C-­‐‑domain	  
contains	  residues	   for	  phosphorylation.	  TCFs	  combine	  with	  serum	  response	   factors	  
using	  their	  B-­‐‑domain	  to	  trigger	  the	  expression	  of	  important	  immediate	  early	  genes	  
(IEGs).	  These	  IEGs	  function	  as	  transcription	  factors	  for	  countless	  proteins	  that	  shift	  
the	   physiological	   state	   of	   cells	   into	   proliferation,	   differentiation	   and	   migration	  
(Vickers	  et	  al.	  2004;	  Yoon	  and	  Seger	  2006).	  	  
	   Elk-­‐‑1	  is	  one	  of	  the	  most	  well-­‐‑characterized	  TCF	  target	  of	  the	  MAPK	  pathway,	  
particulary	   ERK	   (Gille,	   Sharrocks,	   and	   Shaw	   1992).	   ERK	   binds	   the	   D-­‐‑domain	   and	  
another	  hydrophobic	  region	  of	  Elk-­‐‑1	  and	  phosphorylates	  Elk-­‐‑1’s	  C-­‐‑domain	  (Ser	  383,	  
389)	  enhancing	  its	  binding	  to	  DNA	  (Marais,	  Wynne,	  and	  Treisman	  1993).	  	  
	   Activated	  Elk-­‐‑1	  promotes	  the	  rise	  of	  the	  proto-­‐‑oncogene	  c-­‐‑Fos	  (Gilley,	  March,	  
and	   Cook	   2009).	   c-­‐‑Fos	   functions	   as	   a	   potent	   transcription	   factor	   that	   promotes	  
proliferation	  and	  regulates	  differentiation	  in	  cells.	  It	  is	  absent	  in	  quiescent,	  wild-­‐‑type	  
cells	  and	  exhibits	  a	  transient	  expression	  pattern	  that	  can	  vary	  from	  a	  few	  minutes	  to	  
several	  hours	  after	  stimulation	  depending	  on	  its	  transcriptional	  activation	  and	  post	  
translational	  protein	   stability	   (Eferl	   and	  Wagner	  2003).	   c-­‐‑Fos	   is	   stabilized	  by	  ERK	  
phosphorylation	   (Ser	   362,	   Ser	   374),	   otherwise	   it	   undgergoes	   rapid	   degradation.	  
Therefore	  ERK	  not	  only	  initiates	  c-­‐‑Fos	  mRNA	  expression	  through	  activation	  of	  Elk-­‐‑1,	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but	   also	   stabilizes	   the	   resulting	   c-­‐‑Fos	  protein	  by	  post-­‐‑transcriptional	  modification	  
(Gilley	  et	  al.	  2009).	  c-­‐‑Fos	  expression	  determines	  the	  number	  and	  type	  of	  genes	  that	  
are	   activated	   (Eferl	   and	   Wagner	   2003).	   Consequently,	   robust	   activation	   and	  
functioning	  of	  c-­‐‑Fos	  seems	  to	  be	  entirely	  dependent	  upon	  sustained	  activation	  of	  ERK.	  	  
	  
RSKs	  and	  Paxillin	  
	   An	  important	  functional	  mediator	  of	  MAPK	  signaling	  is	  ribosomal	  S6	  kinase	  
(RSK)	  proteins.	  RSK	  proteins	  are	  90	  kDA	  Ser/Thr	  kinases	  composed	  of	  4	   isoforms	  
(RSK1,	  RSK2,	  RSK3,	  RSK4).	  RSKs	  are	  directly	  activated	  by	  ERK	  1/2.	  RSKs	  have	  been	  
implicated	   in	   the	   regulation	   of	   diverse	   cellular	   processes	   including	   protein	  
expression,	  cell	  proliferation,	  cell	  survial,	  cell	  growth	  and	  motility	  (Anjum	  and	  Blenis	  
2008).	  RSK	  mediates	  cell	  proliferation	  by	  stabilizing	  c-­‐‑Fos,	  and	  mediates	  cell	  survival	  
through	  suppression	  of	  Bad-­‐‑mediated	  apoptosis	  (Shimamura	  et	  al.	  2000).	  RSK1	  binds	  
and	   enhances	   the	   function	   of	   the	   transcriptional	   factors	   CREB	   (cAMP	   response	  
element-­‐‑binding	  protein),	  serum	  response	  factor	  (SRF)	  and	  many	  others	  to	  further	  
promote	   cell	   survival	   (Rivera	   et	   al.	   1993;	   Xing,	   Ginty,	   and	   Greenberg	   1996).	   RSK	  
mediated	   cell	   motility	   is	   a	   result	   of	   the	   activated	   Filamin	   A	   (FLNA)	   protein	   that	  
regulates	  the	  actin	  cytoskeleton	  (Woo	  et	  al.	  2004)	  
Paxillin	   is	  a	   focal	  adhesion	  protein	   that	   transmits	  extracellular	  signals	   from	  
integrin	  proteins	  and	  growth	  factors	  to	  promote	  efficient	  cellular	  migration	  through	  
assembly	  of	  focal	  contacts	  (Brown	  and	  Turner	  2004).	  Focal	  contacts	  provide	  adhesion	  
of	  the	  lamellipodia	  to	  the	  extracellular	  surface	  and	  traction	  during	  cellular	  movement	  
(Gerthoffer	  2007).	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Paxillin	   is	   critical	   for	   cellular	  migration	  as	  demonstrated	  by	   the	   inability	  of	  
paxillin	   knockout	  NBTII	   bladder	   tumor	   cells	   to	  migrate	   and	   subsequent	   rescue	   of	  
migration	  through	  transfection	  of	  wild-­‐‑type	  paxillin	  (Petit	  et	  al.	  2000).	  Upon	  cellular	  
stimulation,	  ERK	  and	  Paxillin	  interact	  in	  a	  form	  of	  symbiosis	  where	  they	  facilitate	  each	  
other’s	   activation.	   Paxillin	   recruits	   a	   proto-­‐‑oncogene	   known	   as	   Src	   to	   form	   the	  
intracellular	  focal	  contact.	  Src	  phosphorylates	  paxillin	  at	  Y118	  which	  creates	  an	  ERK	  
binding	  site	  (Ishibe	  et	  al.	  2003).	  Paxillin	  promotes	  the	  activation	  of	  ERK	  by	  binding	  
both	  Raf	  and	  MEK	  in	  close	  proximity	  to	  ERK.	  Activated	  ERK,	  in	  turn,	  phosphorylates	  
paxillin.	  Phosphorylation	  by	  ERK	  increases	  paxillin’s	  association	  with	  focal	  adhesion	  
kinase	  (FAK)	  which	  triggers	  cell	  spreading	  and	  motility	  (Liu	  et	  al.	  2002).	  
PI3K/AKT/p70S6K	  pathway	  
Discovery	  of	  PI3K	  pathway	  components:	  
	   The	  PI3Kinase	  pathway	  via	  AKT	  leads	  to	  the	  suppression	  of	  apoptosis	  (Figure	  
18),	  and	  cell	  cycle	  arrest	  while	  promotion	  of	  cellular	  growth,	  protein	  synthesis,	  cell-­‐‑
cycle	   progression,	   metabolism	   and	   migration.	   The	   protein	   p70	   S6K	   was	   first	  
discovered	   in	  1970	  described	  to	  be	  “a	  kinase	  that	   transfers	  γ-­‐‑phosphoryl	  group	  of	  
GTP	   to	   40S	   ribosomal	   unit.”	   The	   phosphorylation	   of	   the	   40S	   ribosomal	   unit	   was	  
correlated	   with	   increased	   protein	   synthesis.	   After	   the	   discovery	   of	   p85	   S6K,	   the	  
question	  became,	  which	  S6K,	  p70	  or	  p85	  that	  was	  doing	  the	  phosphorylation	  of	  small	  
40s	  ribosomal	  units?	  It	  was	  later	  decided	  that	  both	  S6Ks	  carry	  out	  the	  same	  function	  
but	  in	  different	  compartments:	  p85	  S6K	  functions	  in	  the	  nucleus	  due	  to	  its	  nuclear	  
localization	  signal	  while	  p70S6K	  primarily	  functions	  in	  the	  cytoplasm.	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p70S6K	   activation	   was	   associated	   with	   IL-­‐‑2	   treatment	   even	   before	   the	  
discovery	   of	   the	   IL-­‐‑2	   receptor	   β	   and	   γ.	   It	   was	   initially	   believed	   that	   p70S6K	  was	  
activated	  primarily	  by	  PKC	  but	  it	  later	  became	  clear	  that	  there	  was	  an	  unknown	  factor	  
responsible	  for	  p70S6K	  that	  was	  independent	  of	  PKC.	  This	  factor	  was	  identified	  to	  be	  
PI3	  Kinase.	  	  
PI3	  Kinase	  is	  a	  heterodimeric	  enzyme	  consisting	  of	  a	  regulatory	  subunit	  (p85)	  
and	  a	  catalytic	  subunit	  (p110).	  It	  can	  transduce	  signals	  from	  activated	  tysoine	  kinase	  
resptors,	  G	  protein-­‐‑coupled	  receptors	  and	  from	  activated	  RAS.	  PI3	  Kinase	  activation	  
was	   associated	   with	   the	   treatment	   of	   several	   cytokines	   and	   first	   reported	   to	   be	  
activated	  by	  IL-­‐‑2	  in	  1991.	  Follow	  up	  studies	  found	  that	  the	  SH2	  domain	  of	  PI3	  Kianse	  
is	  utilized	  for	  interaction	  with	  the	  IL-­‐‑2	  receptor.	  In	  1996,	  Wortmannin,	  a	  PI3	  Kinase	  
inhibitor,	  inhibited	  p70S6K	  activation	  in	  Jurkat	  T-­‐‑cell	  line,	  successfully	  establishing	  
the	  connection	  between	  PI3K	  and	  p70S6K.	  The	  protein	  AKT	  was	  later	  reported	  to	  be	  
a	  mediator	  between	  PI3K	  and	  p70S6K.	  	  
	  
AKT	  and	  mTOR	  activation	  
PI3K	  binds	  to	  phosphorylated	  IL-­‐‑2	  receptor	  β	  through	  scaffolding	  proteins	  Shc	  
and	  Grb2-­‐‑Gab2	  complex.	  This	  leads	  to	  PI3K	  phosphorylation	  and	  activation	  (Gu	  et	  al.	  
2000).	  The	  activated	  PI3K	  converts	  the	  plasma	  membrane	  lipid	  phosphatidylinositol-­‐‑
4,5-­‐‑	  bisphosphate	  [PI(4,5)P2	  or	  PIP2	  ]	  to	  phosphatidyl-­‐‑	  inositol-­‐‑3,4,5-­‐‑trisphosphate	  
[PI(3,4,5)P3	  or	  PIP3	  ]	  (Lawlor	  and	  Alessi	  2001).	  	  
The	  proteins	  AKT	  and	  PDK1	  contain	  pleckstrin-­‐‑homology	  (PH)domains	  that	  
bind	  PIP3,	  and	  consequently	  aggregate	  in	  regions	  of	  PI3K	  activity.	  The	  proximity	  of	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PDK1	  with	  AKT	  facilitates	  PDK1’s	  phosphorylation	  of	  AKT	  (Lawlor	  and	  Alessi	  2001).	  
Simultaneously	   a	   negative	   regulator	   of	   this	   pathway,	   “Phosphatase	   and	   tensin	  
homologue	   deleted	   on	   chromosome	   ten”	   (PTEN),	   actively	   reduces	   the	   amount	   of	  
PIP3.	   PTEN	   as	   a	   result	   discourages	   AKT	   and	   PDK1	   aggregation.	   Since	   the	   AKT	  
pathway	  is	  associated	  with	  cellular	  survival	  and	  migration,	  PTEN	  functions	  as	  a	  tumor	  
suppressor	  through	  its	  negative	  regulation	  of	  AKT	  (Hopkins	  et	  al.	  2014).	  	  
	   Following	   activation,	   AKT	   activates	   the	   mammalian	   target	   of	   rapamycin	  
complex	  1(mTORC1)	  by	  phosphorylation	  of	  the	  tuberous	  sclerousis	  complex	  (TSC1-­‐‑
TSC2	  )	  a	  mTORC1	  inhibitor	  (Manning	  et	  al.	  2002).	  mTORC1	  subsequently	  promotes	  
cell	  survival	  by	  direct	  phosphorylation	  of	  p70	  S6K	  	  and	  elF4E-­‐‑binding	  proteins	  (4E-­‐‑
BPs)	  to	  promote	  protein	  translation	  (Aoki,	  Blazek,	  and	  Vogt	  2001;	  Nave	  et	  al.	  1999).	  
AKT	  also	  engages	  phosphorylation	  of	  multiple	  proteins	  in	  the	  cytoplasm	  and	  nucleus	  
leading	  cell	  survival,	  cell-­‐‑cycle	  progression	  and	  migration.	  	  
Rapamycin	  is	  a	  macrolide	  and	  inhibitor	  of	  mTORC1.	  It	  was	  discovered	  in	  soil	  
samples	  from	  Easter	  Islands	  produced	  by	  the	  bacterium	  Streptomyces	  hygroscopicus	  
(VÉZINA,	  KUDELSKI,	  and	  SEHGAL	  1975).	  Initially,	  Rapamycin	  was	  characterized	  as	  
an	   anti-­‐‑fungal	   agent	   but	   it	   was	   soon	   discovered	   to	   exhibit	   immunosuppressive	  
functions	  by	  inhibiting	  T-­‐‑cell	  proliferation,	  and	  inhibiting	  protein	  synthesis	  (Dumont	  
and	   Su	   1995;	   Gonzalez	   et	   al.	   2001).	   Rapamycin	   binds	   FKBP12	   and	   this	   dimeric	  
complex	   targets	   and	   deactivates	  mTORC1	   (Lorenz	   and	   Heitman	   1995).	   Currently,	  
Rapamycin	   is	   used	   to	   inhibit	   transplant	   rejection	   primarily	   by	   inhibiting	   IL-­‐‑2	  
production	  and	  IL-­‐‑2	  mediated	  signaling	  (Shan	  et	  al.	  2015).	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STAT	  5	  
	   There	  are	  seven	  mammalian	  stats	  (STAT	  1,	  2,	  3,	  4,	  5A,	  5B,	  and	  6).	  STATs	  are	  a	  
crucial	  part	  of	  signal	  transmission	  from	  all	  members	  of	  the	  hematopoietic	  family	  of	  
cytokines	  as	  well	  as	  many	  hormones	  (eg.	  leptin	  and	  growth	  hormone).	  JAK	  proteins	  
respond	   to	   receptor	   activation	   by	   phosphorylating	   docking	   sites	   for	   STAT	   on	   the	  
receptor	   itself.	  When	   bound	   to	   the	   receptor,	   STATS	   become	   phosphorylated,	   they	  
form	  homodimers	  and	  translocate	  into	  the	  nucleus.	  In	  the	  nucleus,	  STAT	  dimers	  bind	  
specific	   sequences	   termed	  γ-­‐‑activated	  sequences	   (GAS)	   in	   the	  promoter	   regions	  of	  
their	   target	  genes	  and	  stimulate	  transcription	  (Johnston	  et	  al.	  1995;	  W.	  Kuziel	  and	  
Greene	   1990;	   Mahmud,	   Manlove,	   and	   Farrar	   2013).	   In	   response	   to	   IL-­‐‑2,	   STAT	   5	  
regulates	  immediate	  early	  cytokine-­‐‑inducible	  genes	  such	  as	  pim-­‐‑1	  (mitogenesis),	  bcl-­‐‑




















Figure	  17.	  IL-­‐‑2	  mediated	  MAPK	  pathway	  activation	  outline	  in	  lymphocytes.	  







Figure	  18.	  IL-­‐‑2	  mediated	  PI3K	  pathway	  activation	  outline	  in	  lymphocytes.	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IL-­‐‑2	  activates	  the	  MAPK	  pathway	  in	  VSMCs.	  	  
To	   determine	   whether	   IL-­‐‑2	   activates	   the	   MAPK	   pathway	   in	   VSMCs,	   two	  
integral	   components	   of	   these	   two	   pathways	   were	   monitored	   in	   cultured	   human	  
VSMCs	   for	  phosphorylation	  after	   the	  addition	  of	   IL-­‐‑2.	  Both	  an	   IL-­‐‑2	   treatment	   time	  
course	   and	   dose	   dependence	   experiments	   were	   carried	   out	   and	   lysates	   were	  
collected	  as	  outlined	  in	  the	  materials	  and	  methods.	  Western	  blot	  analysis	  shows	  that	  
band	   intensity	   indicating	  phosphorylated	  ERK	  and	  p38	  were	  significantly	  elevated	  
after	  IL-­‐‑2	  treatment	  at	  15	  minutes	  and	  30	  minutes	  respectively	  (Figure	  19).	  After	  a	  
60-­‐‑minute	  treatment	  with	  IL-­‐‑2,	  maximum	  activation	  of	  ERK	  and	  p38	  was	  observed	  at	  
IL-­‐‑2	  concentrations	  of	  25	  ng/mL	  and	  50	  ng/mL	  respectively	  (Figure	  20).	  	  
Our	  data	  suggests	  that	  IL-­‐‑2	  phosphorylates	  ERK	  and	  p38.	  ERK,	  activation	  in	  
response	   to	   IL-­‐‑2	   is	   transient	   and	   peaks	   at	   15	  minutes	   and	   returns	   to	   basal	   level	  
phosphorylation.	   P38	   phosphorylation	   is	   relatively	   more	   sustained	   than	   ERK	  
phosphorylation	  since	  band	  intensity	  is	  increased	  at	  30	  minutes	  and	  maintained	  at	  
60	  minutes.	  Since	  ERK	  and	  p38	  are	  integral,	  downstream	  components	  of	  the	  MAPK	  
pathway,	  and	  phosphorylation	  is	  known	  to	  activate	  these	  proteins,	  we	  can	  infer	  that	  
IL-­‐‑2	  activates	  the	  MAPK	  pathway.	  	  
IL-­‐‑2	  activates	  the	  PI3K	  pathway	  in	  VSMCs	  
	   Similar	  to	  our	  approach	  to	  gauge	  the	  MAPK	  pathway	  activation	  in	  response	  to	  
IL-­‐‑2,	  we	  determined	  activation	  of	  the	  PI3K	  pathway	  by	  monitoring	  phosphorylation	  
of	  two	  of	  its	  integral	  components:	  AKT,	  S6-­‐‑K.	  Westernbot	  analysis	  shows	  that	  band	  
intensities	  indicating	  phosphorylation	  of	  AKT	  is	  significantly	  elevated	  with	  treatment	  
of	  25	  ng/mL	  and	  50	  ng/mL	  of	  IL-­‐‑2	  and	  an	  attenuated	  response	  was	  observed	  at	  the	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higher	  dose	  IL-­‐‑2	  concentration	  of	  100ng/mL	  (Figure	  21).	  Phosphorylation	  of	  S6K	  was	  
observed	  after	  treatment	  with	  50	  ng/mL	  and	  100	  ng/mL	  of	  IL-­‐‑2.	  
	   Our	  data	  suggest	  that	  both	  AKT	  and	  S6K	  are	  phosphorylated	  in	  VSMCS	  after	  
the	   treatment	  with	   IL-­‐‑2.	  Since	   these	  proteins	  are	   integral	   components	  of	   the	  PI3K	  
pathway,	  it	  is	  reasonable	  to	  surmise	  that	  PI3K	  pathway	  is	  activated	  in	  VSMCs	  after	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Figure	  19.	  IL-­‐‑2	  promotes	  time	  dependent	  phosphorylation	  of	  MAPK	  Pathway.	  	  
VSMCs	  were	  cultured	   in	  75	  cm2	  flasks	  for	  72	  hrs	  followed	  by	  a	  48	  hr.	  serum	  starvation.	  VSMCs	  
were	  treated	  with	  50	  ng/mL	  of	   IL-­‐‑2	  and	   incubated	  for	  a	  range	  of	   time	  points.	  Cells	  were	   lysed	  
using	   phosphotase	   inhibitors	   (Roche,	   Indianapolis,	   Indiana)	   and	   protein	   concentrations	   were	  
determined	  by	  BCA.	  Equal	  amounts	  of	  their	  protein	  extracts	  were	  separated	  by	  SDS-­‐‑PAGE	  on	  4-­‐‑
12%	   (w/v)	   polyacrylamide	   resolving	   gels	   and	   the	   proteins	   were	   transferred	   onto	   a	   PVDF	  
membrane.	   The	   membrane	  was	   probed	  with	   the	   indicated	   primary	   antibody,	   followed	   by	   its	  
corresponding	  secondary	  antibody	  conjugated	  with	  HRP.	  The	  membrane	  was	  developed	  using	  an	  
ECL	  substrate	  and	  visualized	  using	  the	  ChemiDoc	  MP	   imaging	  system	  (Bio-­‐‑Rad,	  Hercules,	  CA).	  
(n=3)	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Figure	  20.	  IL-­‐‑2	  promotes	  dose	  dependent	  phosphorylation	  of	  MAP	  Kinase	  Pathway.	  VSMCs	  
were	   cultured	   in	   75	   cm2	   flasks	   for	   72	   hrs	   followed	   by	   a	   48	   hr.	   serum	   starvation.	   Various	  
concentrations	  of	  IL-­‐‑2	  were	  added	  to	  the	  cells	  and	  the	  cells	  were	  incubated	  at	  37ºC	  for	  60	  min.	  Cell	  
were	  lysed	  using	  phosphotase	  inhibitors	  (Roche,	  Indianapolis,	  Indiana)	  and	  protein	  concentrations	  
were	  determined	  by	  BCA.	  Equal	  amounts	  of	  their	  protein	  extracts	  were	  separated	  by	  SDS-­‐‑PAGE	  on	  
4-­‐‑12%	   (w/v)	   polyacrylamide	   resolving	   gels	   and	   the	   proteins	   were	   transferred	   onto	   a	   PVDF	  
membrane.	   The	   membrane	   was	   probed	   with	   the	   indicated	   primary	   antibody,	   followed	   by	   its	  
corresponding	  secondary	  antibody	  conjugated	  with	  HRP.	  The	  membrane	  was	  developed	  using	  an	  
ECL	   substrate	   and	  visualized	  using	   the	   ChemiDoc	  MP	   imaging	   system	  (Bio-­‐‑Rad,	  Hercules,	  CA)).	  
(n=3)	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Figure	  21.	  IL-­‐‑2	  promotes	  dose	  dependent	  phosphorylation	  of	  PI3K/AKT/S6	  Kinase	  Pathway.	  
VSMCs	  were	   cultured	   in	   75cm2	   flasks	   for	   72hrs	   followed	   by	   a	   48hr.	   serum	   starvation.	   Various	  
concentrations	  of	  IL-­‐‑2	  were	  added	  to	  the	  cells	  and	  the	  cells	  were	  incubated	  at	  37ºC	  for	  60	  minutes.	  
Cell	  were	  lysed	  using	  phosphotase	  inhibitors	  (Roche)	  and	  protein	  concentrations	  were	  determined	  
by	  BCA.	  Equal	   amounts	  of	   their	   protein	   extracts	  were	   separated	   by	   SDS-­‐‑PAGE	  on	  4-­‐‑12%	  (w/v)	  
polyacrylamide	   resolving	   gels	   and	   the	   proteins	   were	   transferred	   onto	   a	   PVDF	   membrane.	   The	  
membrane	   was	   probed	   with	   the	   indicated	   primary	   antibody,	   followed	   by	   its	   corresponding	  
secondary	  antibody	  conjugated	  with	  HRP.	  The	  membrane	  was	  developed	  using	  an	  ECL	  substrate	  
and	  visualized	  using	  the	  ChemiDoc	  MP	  imaging	  system	  (Biorad).	  (n=3)	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Summary	  and	  Discussion	  
It	   is	   evident	   from	   our	   results	   that	   IL-­‐‑2	   activates	   established	   pathways	  
originating	  from	  the	  intracellular	  components	  of	  the	  IL-­‐‑2	  receptor	  β	  and	  γ	  subunits.	  
We	   have	   identified	   IL-­‐‑2	  mediated	   activation	   of	   ERK,	   p38,	   AKT	   and	   S6K	   in	   VSMCs	  
(Figure	  20,	  21,	  22).	  These	   findings	  suggest	   that	   the	  well	  established	   IL-­‐‑2	  mediated	  
activation	  of	  MAPK	  pathway	  and	  PI3K	  pathways	  in	  lymphocytes	  is	  most	  likely	  also	  
functioning	  in	  VSMCs.	  	  	  
The	  pattern	  of	  expression	  elicited	  by	  the	  hour	  long	  treatment	  for	  ERK,	  p38	  and	  
AKT	  was	  unexpected.	  Our	  dose	  response	  was	  tested	  at	  one	  hour	  to	  specifically	  gauge	  
sustained	   activation	   of	   these	   downstream	   signaling	   pathways.	   The	   dose	   response	  
results	   allude	   to	   the	   possibility	   that	   VSMC’s	   response	   to	   IL-­‐‑2	   is	   biphasic	   and	  
discriminates	  between	  low	  and	  high	  concentrations	  of	  IL-­‐‑2.	  With	  lower	  doses	  of	  IL-­‐‑2	  
(25ng/mL)	  we	  see	  a	  strong,	  sustained	  ERK	  activation,	  thus,	  the	  immediate	  early	  gene	  
c-­‐‑fos	  should	  be	  elevated	  within	  the	  first	  few	  hours	  through	  interaction	  between	  ERK	  
and	  Elk-­‐‑1.	  This	  is	  known	  to	  lead	  to	  cell	  cycle	  progression	  (Eferl	  and	  Wagner	  2003).	  
The	  activation	  of	  p38	  is	  observed	  after	  treatment	  with	  a	  higher	  dose	  of	  IL-­‐‑2	  and	  has	  
been	  associated	  with	  the	  expression	  of	  inflammatory	  genes.	  AKT	  phosphorylation	  in	  
response	   to	   IL-­‐‑2	   treatment	  of	  VSMCs	   supports	   the	   idea	   that	   IL-­‐‑2	  elicits	   a	  biphasic	  
response.	  	  
ERK	  and	  PI3K/AKT	  pathways	  have	  been	  implicated	  in	  promoting	  migration	  
(Anjum	  and	  Blenis	  2008;	  Hopkins	  et	  al.	  2014;	  Shiojima	  and	  Walsh	  2002;	  Stambolic	  
and	  Woodgett	  2006).	  ERK	  activation	   in	  VSMCs	  result	   in	  a	  early	  and	   late	  response;	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early	   activation	   triggers	   migration	   while	   a	   later,	   more	   sustained	   activation	   is	  
associated	  with	  proliferation	  (Nelson	  et	  al.	  1998).	  	  	  
Activated	   ERK	   phosphorylates	   paxillin	   in	   response	   to	   migration	   inducing	  
stimuli.	   Phosphorylated	   paxillin	   is	   critical	   for	   migration	   since	   it	   initiates	   the	  
formation	  of	  focal	  contacts	  necessary	  of	  forming	  a	  bridge	  between	  the	  extracellular	  
matrix	  and	  the	  cytoskeleton.	  This	  provides	  enough	  traction	  for	  cellular	  mobilization	  
(Ishibe	  et	  al.	  2003;	  Woodrow	  et	  al.	  2003).	  Other	  proteins	  activated	  by	  ERK	  that	  lead	  
to	   cell	  motility	   are	   calpain,	  MLCK	  and	   caldesmon	   (Goldman,	  Zhong,	   and	  Liu	  2007;	  
Huang	  et	  al.	  2004;	  Klemke	  et	  al.	  1997).	  Proteins	  known	  to	  be	  activated	  by	  the	  MAPK	  
pathway	  and	  associated	  with	  VSMC	  migration	  should	  be	  observed	  in	  the	  context	  of	  
IL-­‐‑2	  treatment	  to	  better	  understand	  the	  specific	  mechanism	  activated	  by	  IL-­‐‑2.	  
Our	  consistent	  observation	  of	  a	  biphasic	  response	  provides	  strong	  reasoning	  
for	   follow-­‐‑up	   studies	   to	   observe	   downstream	   targets	   of	   both	   the	  MAPK	   and	   PI3K	  
pathways	  to	  better	  discern	  the	  function	  elicited	  by	  low	  concentration	  of	  IL-­‐‑2	  versus	  a	  
high	  concentration	  of	  IL-­‐‑2.	  Studying	  the	  downstream	  targets	  of	  ERK,	  p38,	  AKT	  also	  
would	  provide	  a	  much	  more	  polarized	  view	  of	  the	  VSMC	  response	  to	  IL-­‐‑2	  since	  the	  
MAPK	   proteins	   and	   PI3K	   proteins	   are	   substrates	   to	   an	   overlapping	   upstream	  
sequence	  of	  kinase	  activations.	  	  	  
STAT	  5	  pathway	  is	  also	  a	  well	  established	  pathway	  activated	  by	  IL-­‐‑2	  in	  VSMCs	  
and	  warrants	  our	  attention.	  Their	  activation	  has	  been	  associated	  with	  cell	  survival	  
and	  cell	  proliferation	  and	  would	  best	  overlap	  with	  a	  signal	  from	  ERK.	  	  	  
Our	   brief	   mapping	   of	   IL-­‐‑2	   mediated	   signals	   using	   the	   MAPK	   and	   PI3K	  
pathways	  in	  VSMCs	  is	  novel	  and	  provides	  clues	  as	  to	  the	  physiological	  role	  that	  IL-­‐‑2	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plays	   in	   regulating	  VSMC	   function.	  However,	   these	   results	   do	   not	   provide	   enough	  
information	  to	  appreciate	  the	  definitive	  function	  of	  the	  pathways	  initiated	  by	  IL-­‐‑2.	  We	  
must	  compile	  data	  from	  downstream	  targets	  of	  MAPK,	  PI3K	  and	  JAK/STAT	  pathways,	  
along	  with	  gene	  expression	  micro	  arrays	  in	  IL-­‐‑2	  treated	  VMSCs	  to	  more	  effectively	  
























	  	  	  	  Conclusion	  and	  Future	  Studies	  
	   Atherosclerosis	   is	   the	   leading	   cause	   of	   mortality	   in	   patients	   with	  
cardiovascular	  disease.	  It	  is	  an	  inflammatory	  disorder	  of	  medium	  and	  large	  arteries	  
centered	  around	  the	  formation	  of	  plaques.	  After	  endothelial	  cell	  activation,	  formation	  
of	  the	  atheroscleorotic	  plaques	  relies	  on	  VSMC	  proliferation	  and	  foam	  cell	  maturation	  
(Bentzon	   et	   al.	   2014).	   During	   the	   development	   of	   atherosclerosis,	   numerous	  
cytokines	  and	  growth	  factors	  are	  elevated	  within	  plaques	  (Kleemann	  et	  al.	  2008).	  The	  
complexity	  of	  cytokine	  mediated	  cellular	  communication	  among	  VSMCs,	  endothelial	  
cells,	  platelet	  cells	  and	  fibroblasts	  during	  the	  progression	  of	  atherosclerosis	  is	  a	  major	  
barrier	   to	   the	   identification	  of	  primary	   factors	   that	  maybe	  responsible	   for	   inciting	  
plaque	  formation.	  It	  is	  also	  difficult	  to	  later	  characterize	  the	  role	  an	  individual	  factor	  
plays	  in	  orchestrating	  inflammation	  that	  drives	  the	  progression	  of	  atherosclerosis	  in	  
the	  presence	  of	  numerous	  others.	  	  
	   Vascular	   smooth	   muscle	   cell	   proliferation	   and	   migration	   are	   critical	  
components	  of	  the	  progression	  of	  atherosclerosis,	  yet	  we	  do	  not	  fully	  understand	  its	  
underlying	  mechanism	  (Orlandi	  2015).	  The	  following	  question	  remains:	  What	  are	  the	  
primary	  molecular	   agents	  whereby	  VSMCs	   are	   induced	   to	  migrate	   and	  proliferate	  
during	  the	  formation	  of	  atherosclerotic	  plaques?	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   In	  a	  recent	  publication,	  we	  reported	  the	  deposition	  of	  IL-­‐‑2	  within	  the	  smooth	  
muscle	  layer	  of	  the	  aorta.	  We	  later	  reported	  that	  VSMCs	  express	  IL-­‐‑2Rβ	  (Miller	  et	  al.	  
2012).	   Due	   to	   the	   co-­‐‑localization	   of	   IL-­‐‑2	   with	   VSMCs	   and	   the	   expression	   of	   IL-­‐‑2	  
receptor	  subunits	  on	  VSMCs,	  we	  suspected	  that	  IL-­‐‑2	  interacts	  with	  VSMCs	  through	  
the	  IL-­‐‑2	  receptor.	  Considering	  IL-­‐‑2’s	  well-­‐‑characterized	  proliferative	  function	  among	  
immune	   cells	   we	   hypothesized	   that	   IL-­‐‑2	   causes	   proliferation	   and	   migration	   of	  
vascular	  smooth	  muscle	  cells	  of	  the	  aorta	  and	  elicits	  this	  function	  through	  the	  IL-­‐‑2	  
receptor.	  	  
In-­‐‑vitro	  IL-­‐‑2	  treatment	  of	  primary	  VSMCs	  derived	  from	  human	  aorta	  and	  ex-­‐‑
vivo	   IL-­‐‑2	   treatment	   of	   aortic	   explants	   produced	   a	   demonstrable	   proliferative	   and	  
migratory	   effect	   (Chapters	   3	   and	   4).	   Furthermore,	   we	   uncovered	   IL-­‐‑2	   mediated	  
activation	  of	  major	  signaling	  pathways	  in	  VSMCs	  (Chapter	  6).	  These	  pathways	  have	  
not	  only	  been	  previously	  associated	  with	  IL-­‐‑2	  receptor	  activation	  in	  lymphocytes,	  but	  
also	  allude	  to	  underlying	  mechanisms	  that	  actuate	  physiologic	  change.	  	  
To	  further	  develop	  our	  understanding	  of	  IL-­‐‑2	  mediated	  VSMC	  migration,	  it	  is	  
important	  to	  characterize	  phenotypic	  changes	  of	  VSMCs	  during	  migration	  in	  response	  
to	  IL-­‐‑2.	  To	  best	  accomplish	  this,	  VSMCs	  can	  be	  treated	  with	  IL-­‐‑2	  and	  fixed	  at	  various	  
time	  points.	  Phase	  contrast	  microscopy	  can	  be	  used	  in	  conjunction	  with	  staining	  of	  
cytoskeletal	   proteins	   such	   as	   actin,	   to	   capture	   and	   assess	   phenotypic	   differences	  
between	  IL-­‐‑2	  treated	  and	  control	  VSMCs	  associated	  with	  migration.	  	  
IL-­‐‑2	  seemed	  to	  elicit	  a	  notable	  proliferative	  response	  in	  VSMCs.	  We	  observed	  
that	  IL-­‐‑2	  treatment	  resulted	  in	  anywhere	  from	  20%-­‐‑50%	  increase	  in	  DNA	  synthesis	  
in	   VSMCs	   relative	   to	   untreated	   VSMCs.	   It	   is	   possible	   that	   IL-­‐‑2	   may	   elicit	   a	   more	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meaningful	  response	  in	  tandem	  with	  other	  factors.	  This	  is	  not	  an	  unusual	  concept	  for	  
IL-­‐‑2	  physiology	  since	  the	  IL-­‐‑2	  mediated	  response	  of	  a	  naïve	  CD4+	  T-­‐‑cell	  is	  very	  weak	  
unless	  it	  is	  preceded	  by	  three	  important	  signals:	  (1)	  activation	  of	  the	  T-­‐‑cell	  receptor	  
(2)	  Cd28	  (3)	  CD40L	  (Smith-­‐‑Garvin,	  Koretzky,	  and	  Jordan	  2009). VSMC’s	  response	  to	  
IL-­‐‑1	  is	  also	  very	  minimal	  until	  combined	  with	  PDGF	  (Bonin,	  Fici,	  and	  Singh	  1989).	  In	  
a	  similar	  manner,	  a	  robust	  response	   to	   IL-­‐‑2	  maybe	  contingent	  upon	  the	  activation	  
state	  of	  VSMCs	  or	  the	  presence	  of	  a	  secondary	  signal.	  	  
The	  cooperative	  effect	  of	  growth	  factors	  is	  generally	  viewed	  as	  a	  checkpoint	  to	  
prevent	  excessive	  proliferation	  of	  cells	  and	   to	   initiate	  proliferation	  only	  when	   it	   is	  
required.	   To	   find	   the	   growth	   factors	   that	   might	   support	   IL-­‐‑2	   mediated	   VSMC	  
proliferation,	  we	  must	  explore	  conditions	  during	  which	  VSMCs	  are	  primed	   for	  cell	  
division.	   VSMCs	   have	   been	   known	   to	   transform	   into	   a	   proliferative	   phenotype	   in	  
response	  to	   inflammatory	  cytokines	  which	  are	  typically	  elevated	  during	  a	  vascular	  
injury,	   autoimmune	   reaction	   or	   during	   the	   chronic	   progression	   of	   atherosclerosis	  
(Rudijanto	  2007).	  Thus	  in	  order	  to	  recreate	  this	  heightened	  state	  within	  VSMCs,	  the	  
proliferative	   response	   of	   VSMCs	   to	   IL-­‐‑2	   should	   be	   tested	   in	   the	   context	   of	  
inflammatory	  cytokines	  such	  as	  PDGF,	  IL-­‐‑1,	  IFN-­‐‑g,	  IL-­‐‑6	  and	  TNF.	  
	   Since	   we	   know	   that	   the	   synthetic	   phenotype	   of	   VSMCs	   is	   more	  
proliferative	  and	  mobile,	  our	   findings	   that	   IL-­‐‑2	   treatment	  causes	  proliferation	  and	  
migration	  raises	  a	  very	  important	  question:	  Does	  IL-­‐‑2	  cause	  VSMCs	  to	  convert	  to	  a	  
synthetic	  phenotype?	  Our	  preliminary	  data	  suggests	  that	  IL-­‐‑2	  does	  seem	  to	  cause	  a	  
switch	  from	  a	  contractile	  to	  a	  synthetic	  phenotype	  based	  on	  the	  expression	  level	  of	  
contractile	   proteins.	   A	   48hr	   IL-­‐‑2	   treatment	   of	   VSMCs	   caused	   a	   sharp	   decline	   in	  
	   79	  
calponin	   expression,	   a	   marker	   of	   contractile	   VSMC	   phenotype	   (n=1)	   but	   the	  
expression	  of	  SMC	  α-­‐‑actin	  was	  not	  altered	  (n=2).	  This	   is	  an	   interesting	  result	   that	  
warrants	   additional	   studies	   monitoring	   all	   known	   markers	   of	   contractile	   VSMCs	  
including	  SMC	  α-­‐‑actin,	  SM22α,	  and	  SMC	  myosin	  heavy	  chain	  11.	  
The	  implications	  of	  finding	  that	  VSMCs	  lose	  contractile	  protein	  expression	  in	  
the	  presence	  of	  IL-­‐‑2	  would	  be	  monumental	  in	  the	  study	  of	  atherosclerosis	  and	  would	  
support	   the	   idea	   that	   VSMCs	   de-­‐‑differentiate.	   This	   finding	   also	   would	   pose	   a	  
significant	   challenge	   to	   recent	   work	   by	   Tang	   et.	   al	   who	   have	   marginalized	   the	  
perception	  that	  contractile	  VSMCs	  are	  able	  to	  revert	  to	  a	  synthetic	  phenotype	  (Tang	  
et	  al.	  2012).	  	  
We	  could	  also	  look	  at	  molecular	  regulators	  of	  differentiation	  in	  VSMCs.	  VSMC	  
differentiation	   is	   thought	   to	   be	   primarily	   under	   the	   direction	   of	   the	   transcription	  
factor	  KLF4	  (Zheng	  et	  al.	  2010).	  Quantifying	  the	  expression	  and	  activation	  of	  KLF4	  
protein	   would	   allow	   us	   to	   track	   the	   components	   responsible	   for	   initiating	   the	  
differentiation	  pathway.	  KLF4	  is	  a	  direct	  target	  of	  ERK;	  We	  have	  demonstrated	  strong	  
activation	  of	  ERK	  1/2	  by	  IL-­‐‑2	  in	  VSMCs	  which	  provides	  a	  persuasive	  antecedent	  for	  
pursuing	  KLF4	  in	  the	  context	  of	  IL-­‐‑2	  treated	  VSMCs.	  
	  
IL-­‐‑2	  receptor	  
In	  VSMCs,	  IL-­‐‑2	  receptor	  β	  and	  γ	  subunits	  have	  been	  reported	  (Liao	  et	  al.	  2013;	  
Miller	  et	  al.	  2012);	  however,	   the	  expression	  of	   the	   IL-­‐‑2	  receptor	  α	  has	  never	  been	  
reported.	  We	  have	  here,	  for	  the	  first	  time	  reported	  the	  presence	  of	  the	  IL-­‐‑2	  receptor	  
α.	  Even	  more	  surprisingly,	  we	  found	  that	  it	  localized	  primarily	  to	  the	  nucleus.	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The	   findings	   of	   the	   nuclear	   IL-­‐‑2	   receptor	   subunits	   raise	   several	   important	  
questions.	  Does	  the	  nuclear	  IL-­‐‑2	  receptor	  α	  bind	  IL-­‐‑2	  and	  if	  so	  how	  does	  it	  get	  access	  
to	  it	  while	  located	  primarily	  on	  the	  nuclear	  envelope?	  Is	  the	  IL-­‐‑2	  receptor	  α	  necessary	  
for	  proper	  IL-­‐‑2	  mediated	  signaling	  in	  VSMCs?	  	  
To	   start	   collecting	   evidence	   to	   answer	   these	   important	   questions,	  we	  must	  
first	   determine	   if	   IL-­‐‑2	   binds	   its	   receptor	   components	   in	   VSMCs	   by	  
immunoprecipitation.	  Although	  this	  seems	  simple	  and	  obvious,	  we	  have	  not	  actually	  
proven	  that	  IL-­‐‑2	  necessarily	  binds	  the	  IL-­‐‑2	  receptor	  components	  on	  VSMCs.	  	  
Next,	  study	  of	  the	  interaction	  between	  the	  three	  components	   in	  VSMCs	  also	  
would	  offer	  meaningful	  data	  that	  can	  be	  used	  to	  understand	  IL-­‐‑2	  receptor	  function	  in	  
VSMCs.	  We	  should	  compare	  this	  data	  with	  known	  IL-­‐‑2	  receptor	  subunit	  interaction	  
from	  lymphocytes.	  To	  determine	  IL-­‐‑2R	  protein-­‐‑protein	  interaction,	  whole	  cell	  VSMC	  
lysates	   should	   undergo	   immunoprecipitation	   for	   each	   IL-­‐‑2	   receptor	   subunit.	  
Immunoprecipitated	  samples	  should	  be	  probed	  via	  western	  blotting	   for	  remaining	  
receptor	  components.	  For	  example,	  in	  order	  to	  study	  IL-­‐‑2	  receptor	  α	  interaction	  with	  
IL-­‐‑2	  receptor	  β,	  VSMC	  lysates	  will	  be	  immunoprecipitated	  with	  the	  IL-­‐‑2	  receptor	  α	  
antibody.	  Then	  immunopreciptated	  lysates	  should	  be	  probed	  for	  the	  IL-­‐‑2	  receptor	  β	  
using	  western	  blotting	  analysis.	  Detection	  of	  the	  IL-­‐‑2	  receptor	  β	  in	  this	  western	  blot	  
would	  mean	  that	  there	  is	  a	  physical	  interaction	  between	  the	  IL-­‐‑2	  receptor	  α	  and	  β.	  
We	  can	  modify	   this	   experiment	   in	   a	   few	  ways	   to	   glean	  more	   information:	   (1)	  Use	  
lysates	  from	  VSMCs	  treated	  with	  IL-­‐‑2	  and	  compare	  IL-­‐‑2	  receptor	  subunit	  association	  
with	   control	   VSMCs,	   (2)	   Fractionate	   VSMCs	   to	   deduce	   exactly	   in	   which	   cellular	  
compartment	  these	  associations	  take	  place.	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   The	  nuclear	  location	  of	  these	  cytokine	  receptors,	  although	  perplexing,	  
is	  not	  entirely	  a	  new	  finding.	  A	  publication	  from	  almost	  30	  years	  ago	  described	  the	  IL-­‐‑
2	  receptor	  α	  in	  the	  nucleus	  of	  activated	  lymphocytes	  (Jothy	  et	  al.	  1988).	  This	  finding	  
seems	  not	   to	  have	  been	  widely	  accepted	   since	   there	   is	  no	  evidence	  of	   subsequent	  
research	  on	  the	  matter.	  EGF	  receptors	  have	  been	  documented	  to	  transport	  EGF	  into	  
the	  nucleus	  and	  the	  pathway	  responsible	  for	  this	  unusual	  shuttling	  appears	  to	  be	  the	  
result	   of	   the	   translocon,	   Sec61	   (Denks	   et	   al.	   2014).	   Translocons	   typically	   help	   the	  
assembly	  of	  newly	  generated	  proteins	  within	  the	  ER	  onto	  the	  ER	  membrane.	  Sec61	  
seems	  to	  be	  promoting	  the	  insertion	  of	  an	  intact	  protein	  shuttled	  from	  the	  nucleus,	  
into	  the	  ER	  membrane	  (Denks	  et	  al.	  2014;	  Skach	  2007).	  Since	  the	  ER	  membrane	  is	  
continuous	  with	  the	  nucleus,	  this	  may	  be	  a	  possible	  route	  taken	  by	  IL-­‐‑2	  receptors	  in	  
the	  cytoplasmic	  membrane	  to	  shuttle	  bound	  IL-­‐‑2	  in	  closer	  proximity	  to	  IL-­‐‑2	  receptor	  
components	  in	  the	  nuclear	  membrane.	  	  
To	   understand	   how	   the	   IL-­‐‑2	   receptor	   in	   VSMCs	   may	   differ	   from	   the	   IL-­‐‑2	  
receptor	  subunit	  mRNA	  should	  be	  reverse	  transcribed,	  cloned	  and	  sequenced	  from	  
VSMCs.	  Sequencing	  data	  should	  be	  compared	  between	  Genbank	  sequences	  obtained	  
from	   lymphocytes	   to	   identify	   differential	   splicing.	   If	   there	   are	   no	   differences	   in	  
sequencing	  information,	  there	  lies	  a	  possibility	  a	  protein	  that	  is	  tasked	  with	  loading	  
the	   IL-­‐‑2	   receptor	   onto	   the	   ER	   membrane	   or	   a	   shuttling	   protein	   is	   altered	   in	   its	  
expression.	  	  
Another	  important	  area	  of	  research	  is	  the	  identification	  of	  functional	  domains	  
responsible	  for	  localizing	  the	  IL-­‐‑2	  receptor	  to	  the	  nucleus	  versus	  the	  cytoplasm	  and	  
domains	   responsible	   for	   IL-­‐‑2	   receptor	   oligomerization.	   Cloned	   sequences	   can	   be	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modified	   by	   site	   directed	   mutagenesis	   or	   deletion	   of	   various	   regions	   of	   the	   IL-­‐‑2	  
receptor,	  then	  placed	  in	  a	  vector	  containing	  a	  GFP	  or	  flag-­‐‑tag	  sequence.	  These	  cloned	  
sequences	  can	  be	  inserted	  into	  primary	  VSMCs	  using	  an	  adenovirus	  vector.	  The	  GFP	  
and	   flag-­‐‑tagged	   proteins	   will	   be	   used	   as	   identifiers	   to	   distinguish	   these	   receptor	  
proteins	   from	   endogenous	   IL-­‐‑2	   receptor	   proteins.	   GFP	   tagged	   proteins	   can	   be	  
visualized	   by	   confocal	   microscopy	   and	   flag-­‐‑tagged	   proteins	   can	   be	  
immunoprecipitated	   for	   western	   blot	   analysis	   to	   discern	   oligomerization	   state	   or	  
combined	  with	   cell	   fractionation	   for	   assessing	   cellular	   location	   in	   response	   to	   the	  
protein	  modifications.	  This	  would	  be	  a	  systematic	  and	  efficient	  way	  for	  sequencing	  
and	  mapping	  functions	  of	  the	  IL-­‐‑2	  receptor	  protein	  domains	  in	  VSMCs	  
We	  have	  presented	  strong	  evidence	  to	  support	  the	  idea	  that	  IL-­‐‑2	  causes	  smooth	  
muscle	   proliferation	   and	   migration	   and	   uncovered	   an	   underlying	   pathway	   that	  
supports	  these	  functions.	  Since	  significant	  amounts	  of	  IL-­‐‑2	  is	  expressed	  by	  Th1	  cells	  in	  
atherosclerotic	  plaques	  (Frostegård	  et	  al.	  1999),	  IL-­‐‑2	  is	  likely	  exerting	  these	  functions	  
on	  smooth	  muscle	  cells	  found	  in	  atherosclerotic	  plaques.	  Therefore,	  we	  have	  provided	  
substantial	  evidence	  and	  sufficient	  reasoning	  for	  future	  investigations	  to	  observe	  the	  
extent	  of	  IL-­‐‑2’s	  contribution	  toward	  the	  pathogenesis	  of	  atherosclerosis	  using	  animal	  
models.	  	  
Inflammation	   is	   the	   primary	   driving	   force	   for	   countless	   immune	   disorders	  
with	  poorly	  defined	  mechanisms.	  Due	  to	  the	  overarching	  role	  of	   inflammation,	   the	  
study	   of	   atherosclerosis	   helps	   our	   understanding	   of	   other	   chronic	   inflammatory	  
conditions	   of	   the	   vasculature	   such	   Takayasu's	   arteritis,	   Polyarteritis	   nodosa,	   and	  
Kawasaki	   disease.	   There	   is	   already	   some	   evidence	   linking	   increased	   serum	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concentrations	   of	   IL-­‐‑2	   to	   polyarteritis	   nodosa	   and	   increased	   IL-­‐‑2	   receptor	   α	  
expression	  to	  Kawasaki	  disease	  (Grau	  et	  al.	  1989;	  Lang	  et	  al.	  1990).	  Our	  findings	  could	  
directly	  have	  an	  impact	  on	  triggering	  new	  research	  on	  IL-­‐‑2	  mediated	  vasculitis.	  	  	  
Furthermore,	   autoimmune	   conditions	   severely	   cripple	   individuals	   and	  
decrease	   their	   life-­‐‑spans,	   yet	   we	   have	   yet	   to	   develop	   effective	   therapeutic	  
interventions.	  Since	  the	  1990s,	  serum	  IL-­‐‑2	  concentrations	  have	  been	  associated	  with	  
promoting	   peripheral	   tolerance	   primarily	   through	   maintaining	   T-­‐‑regulatory	   cells	  
(Liao	  et	  al.	  2013).	  	  However,	  investigations	  of	  the	  IL-­‐‑2	  receptor	  on	  non-­‐‑lymphoid	  cell	  
lines	  have	  been	  very	  minimal.	  Studies	  show	  that	  IL-­‐‑2Rα	  and	  IL-­‐‑2Rβ	  knockout	  mice	  
develop	  terminal	  autoimmune	  conditions	  such	  as	  hemolytic	  anemia	  and	  ulcerative	  
colitis	  (Felices	  et	  al.	  2014;	  Malek	  2003).	  Our	  findings	  in	  conjunction	  with	  other	  studies	  
that	   found	   IL-­‐‑2	   receptors	   in	   non-­‐‑lymphoid	   cells	   support	   the	   idea	   that	   the	   IL-­‐‑2	  
receptor	  expression	  maybe	   far	  more	  ubiquitous	   than	  previously	  believed	  (Arenas-­‐‑
ramirez	   et	   al.	   2015;	  Gruss	   et	   al.	   1996).	   	   If	   the	   IL-­‐‑2	   receptor	   is	   indeed	   found	   to	  be	  
ubiquitous,	  the	  mechanism	  of	  IL-­‐‑2	  mediated	  peripheral	  tolerance	  and	  IL-­‐‑2	  mediated	  
inflammation	  must	  be	  re-­‐‑investigated.	  Thus,	  each	  new	  discovery	  that	  enhances	  our	  
understanding	  of	  fundamental	  mechanisms	  that	  promote	  atherosclerosis	  leads	  to	  a	  
deeper	   understanding	   of	   our	   entire	   immune	   system	   and	   increases	   the	   number	   of	  













Vascular	  smooth	  muscle	  cell	  cultures	  
	  	  	  	  Human	  artery	  from	  a	  deceased	  donors	  were	  prepared	  as	  follows.	  Adventitia	  and	  
adipose	   tissue	  were	   removed	  using	   sterile	   surgical	   instruments.	   Aortic	   tissue	  was	  
sectioned	  into	  1cmx1cm	  pieces	  and	  placed	  in	  75cm2	  flask	  containing	  complete	  SMCM	  
media	  (Science	  Cell).	  Flasks	  were	  incubated	  in	  a	  humidified	  37°C	  incubator.	  SMCM	  
media	  was	   replaced	   every	  3-­‐‑4	  days	   until	   cells	  were	   observed	   to	   emerge	   from	   the	  
explants.	   After	   cells	   were	   observed,	   explants	   were	   removed.	   	   VSMC	   were	   then	  




	  	  	  	  	  Whole	  cell	  extracts	  from	  VSMCs	  and	  Jurkats	  were	  fractionated	  by	  SDS-­‐‑PAGE	  and	  
transferred	   to	   a	   polyvinylidene	   difluoride	   membrane	   using	   a	   transfer	   apparatus	  
according	  to	  the	  manufacturer’s	  protocols	  (Bio-­‐‑Rad).	  After	  incubation	  with	  5%	  nonfat	  
milk	   in	  TBST	  (10	  mM	  Tris,	  pH	  8.0,	  150	  mM	  NaCl,	  0.5%	  Tween	  20)	   for	  60	  min,	   the	  
membrane	   was	   incubated	   with	   antibodies	   against	   IL-­‐‑2	   receptor	   Α	   (1:1000),	   IL-­‐‑2	  
Receptor	  Β	  (1:500),	  and	  IL-­‐‑2	  Receptor	  Γ	  (1:500)	  at	  4	  °C	  for	  12	  h.	  Membranes	  were	  
washed	  three	  times	  for	  10	  min	  and	  incubated	  with	  a	  1:10,000	  dilution	  of	  horseradish	  
peroxidase-­‐‑conjugated	  anti-­‐‑rabbit	  antibodies	  for	  2	  hrs.	  Blots	  were	  washed	  with	  TBST	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three	  times	  and	  developed	  with	  the	  ECL	  system	  (Amersham	  Biosciences)	  according	  
to	  the	  manufacturer’s	  protocols.	  
	  
Ex-­‐‑Vivo	  Human	  Aortic	  Explant	  Study	  
	  	  	  Human	  artery	   from	  a	  deceased	  donors	  were	  prepared	  as	   follows.	  Adventitia	  and	  
adipose	  tissue	  were	  removed	  using	  sterile	  surgical	  instruments.	  Aorta	  was	  washed	  in	  
Phosphate	   Buffered	   Saline	   and	   sectioned	   into	   small	   (1mm	   x	   2mm)	   segments	   and	  
placed	  lumen	  side	  down	  into	  a	  24	  well	  plate.	  500uL	  of	  DMEM	  containing	  1%	  FBS	  was	  
added	  to	  each	  well	  before	  treatment	  with	  Interleukin-­‐‑2.	  	  
Immunostaining	  
	  	  	  	  	  VSMCs	  were	  plated	  in	  a	  96	  well	  tissue	  culture	  treated	  plate	  and	  allowed	  to	  reach	  
75%	  confluence	   in	  an	   incubator	  at	  37°C	   ,	   and	  5%	  CO2.	  Fixation	  of	   these	  cells	  was	  
carried	  out	  with	  a	  mixture	  of	  methanol:acetic	  acid	  (20:1)	  at	  -­‐‑80°C	  for	  10	  minutes,	  then	  
rinsed	   three	   times	   with	   PBS.	   The	   cells	   were	   later	   incubated	   in	   Odessey	   blocking	  
solution	   (Licor)	   for	   1	   hour.	   Biotinylated	  α-­‐‑CD25,	   α-­‐‑CD122,	   or	   α-­‐‑CD132	   antibodies	  
(Abcam)	   were	   added	   at	   10mg/mL	   in	   Odessey	   Blocking	   buffer	   and	   incubated	  
overnight	  at	  room	  4°C.	  Cells	  were	  then	  washed	  with	  PBST,	  and	  probed	  for	  1.5	  hrs.	  
using	   secondary	   antibodies	   conjugated	   to	   Alexa	   Flour	   (Life	   technologies).	   Images	  
were	  captured	  using	  the	  EVOS	  FL	  imaging	  system	  (Life	  technologies).	  	  
	  
CyQuant	  Cell	  Proliferation	  Assay	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VSMCs	  were	   plated	   into	   96	   well	   plates	   containing	   black	   sides	   and	   optically	   clear	  
bottom	  (Grenier	  bio-­‐‑one)	  at	  a	  density	  of	  250	  cells/well	  in	  complete	  VSMC	  media.	  After	  
72	  hrs.	  of	   incubation	   in	  a	  tissue	  culture	   incubator,	  cells	  were	  washed	  3	  times	  with	  
DMEM	  and	  allowed	  to	  incubated	  another	  48hrs.	  in	  DMEM	  only.	  Next,	  Interleukin-­‐‑2	  
was	  added	  at	  various	  concentrations	  and	  cells	  were	  further	  incubated.	  After	  96	  hrs,	  
cell	   proliferation	   of	   vascular	   smooth	   muscle	   cells	   was	   quantified	   using	   the	  
cyQUANT®	   assay	   (Life	   Technologies).	   Assay	   was	   performed	   following	  
manufacturer’s	   directions.	   The	   resulting	   fluorescence	   was	   read	   on	   a	   Synergy	   H1	  
(Biotek)	  plate	  reader.	  
Alamar	  Blue	  Cell	  Proliferation	  Assay	  
On	   plates	   that	   require	  measurement	   of	   relative	   cell	   density,	   Alamar	   Blue	   reagent	  
(ThermoFisher	  Scientific)	   is	  added	  at	  10%	  of	  the	  volume	  of	  each	  well.	  The	  plate	   is	  
incubated	   at	   37°C	   for	   4hrs.	   before	   measuring	   fluorescence	   using	   the	   Synergy	   H1	  
reader	  (Ex.	  545,	  Em.	  580).	  	  
	  
Migration	  Assay	  
	   Boyden	  chambers	  were	  placed	  in	  24	  well	  plates.	  300uL	  of	  VSMCs	  were	  plated	  
at	   5x104	   cells/well	   onto	   the	   upper	   Boyden	   chambers	   and	   the	   bottom	   chamber	  
received	  750uL	  of	  media.	  After	  a	  24hr	  incubation,	  chambers	  were	  washed	  with	  PBS	  
and	  DMEM	  was	  added	  back	  to	  the	  upper	  (300uL)	  and	  lower	  chambers	  (750uL).	  After	  
another	   24hr.	   incubation,	   media	   inside	   the	   chamber	   was	   replaced	  with	   300uL	   of	  
DMEM	  and	  media	  outside	  the	  chamber	  was	  replaced	  with	  750uL	  of	  DMEM	  containing	  
various	  treatement	  conditions.	  After	  an	  8hr.	  incubation,	  the	  chambers	  were	  fixed	  in	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solution	   of	   methanol	   containing	   2%	   acetic	   acid	   at	   -­‐‑20C.	   The	   upper	   chamber	  
containing	   cells	   were	   scraped	   with	   a	   cotton	   swab	   thoroughly	   to	   remove	   non-­‐‑
migrating	  cells.	  After	  3	  washes	  with	  PBS,	  the	  both	  upper	  and	  lower	  chambers	  were	  
filled	  with	  PBS	  containing	  Sybr	  green.	  	  
	   Flourescent	   images	   were	   captured	   using	   the	   EVOS	   FL	   instrument.	   These	  
images	   were	   processed	   using	   the	   image	   J	   software	   from	   NIH	   which	   allowed	   for	  
accurate	  cell	  counting.	  	  
	  
RT	  PCR:	  
RNA	  from	  cultured	  VSMCs	  were	  used	  for	  cDNA	  synthesis	  with	  random	  hexamers	  and	  
oligo	   dT.	   Human	   IL-­‐‑2	   receptor	   component	   sequences	  were	   used	   to	   design	   intron	  
spanning	  primers	  that	  yielded	  products	  between	  98-­‐‑250bp	  and	  these	  primers	  were	  
optimized	   for	   PCR	   cycling	   conditions.	   CDNA	   samples	   from	  VSMCs	  were	   combined	  
with	   our	   primers	   and	   	   for	   amplification	   of	   regions.	   .	   Products	   were	   run	   in	  
elecrophoresis	   in	   a	   0.5%	   agarose	   gel	   containing	   0.5ug/mL	   ethidium	   bromide	   and	  
visualized	  (figure	  6a)using	  the	  ChemiDoc	  MP	  system	  (BioRad).	  	  
	  
Quantitative	  Real	  time	  PCR:	  
	   VSMCs	  cultured	  in	  SMC	  medium	  from	  Science	  Cell	  were	  transferred	  to	  a	  6	  well	  
plate	  containing	  DMEM	  and	  10%	  FBS.	  72hrs.	  later,	  the	  cells	  were	  washed	  in	  PBS	  and	  
the	  media	   was	   replaced	   with	   DMEM	  media	   with	   and	   without	   various	   treatments	  
(figure	  7).	  Cells	  were	  lysed	  in	  RNA	  lysis	  buffer	  after	  12hrs.	  RNA	  was	  purified	  using	  the	  
RNAeasy	  kit(Quiagen).	  cDNA	  was	  synthesized	  using	  random	  hexamers	  and	  oligo	  dT.	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Quantitative	  Real-­‐‑time	  PCR	   for	  expression	  of	   IL-­‐‑2R 	  was	  performed	  using	  a	  SYBR	  
green	  reaction	  mixture	  (Excella-­‐‑Start,	  GE)	  in	  a	  CFX-­‐‑96	  qPCR	  system.	  Products	  were	  
run	  in	  DNA	  gel	  electrophoresis	  to	  ensure	  singularity	  of	  product	  and	  the	  proper	  size.	  
The	  untreated	  samples	  were	  assigned	  a	  value	  of	  1	  and	  the	  relative	  mRNA	  expression	  
of	   treated	   samples	   were	   calculated	   from	   crossing	   point	   values	   using	   the	    CT	  
method.	  
Cell	  Signaling:	  
All	   VSMCs	   were	   cultured	   in	   75cm2	   flasks	   for	   72hrs	   followed	   by	   a	   48hr.	   serum	  
starvation.	  For	   the	  dose	  dependence	  study,	   increasing	  concentrations	  of	   IL-­‐‑2	  were	  
added	  and	  the	  cultures	  maintained	  at	  37°C	  for	  60	  minutes.	  For	  the	  time	  course	  study,	  
50ng/mL	  of	   IL-­‐‑2	  was	  added	  to	   the	   flasks	  at	  different	   time	  points	  and	   incubated	  at	  
37°C.	   Cells	   were	   lysed	   using	   RIPA	   buffer	   containing	   protease	   and	   phosphatase	  
inhibitors	  (Cell	  signaling)	  and	  protein	  concentrations	  were	  determined	  by	  BCA.	  Equal	  
amounts	   of	   proteins	   from	   each	   sample	  were	   fractionated	   by	   SDS-­‐‑PAGE	   on	   4-­‐‑12%	  
(w/v)	   polyacrylamide	   resolving	   gels.	   Proteins	   were	   transferred	   onto	   a	   PVDF	  
membrane,	  probed	  with	  the	  indicated	  primary	  antibody	  followed	  by	  corresponding	  
secondary	  antibody	  conjugated	  with	  HRP.	  The	  membrane	  was	  developed	  using	  an	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